Executive Summary {#Sec1}
=================

The current report is an overview of current knowledge on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) based on pragmatic review of the available clinical evidence on use of GLP-1 RAs in the management of type 2 diabetes mellitus (T2DM). This report is also a consensus of an expert panel of endocrinologists representing South Asian countries on essential recommendations related to the use of GLP-1 RAs which may aid in rational, smart and safe prescription of GLP-1 RAs in a real-world scenario.

The current report discusses the mechanism of action, classification, pharmacokinetic and pharmacodynamic properties of various GLP-1 RAs. Further, an overview of the prescribing information and recommendations on GLP-1 RA use in T2DM management from diabetic associations across the world is presented.

Clinical evidence (based on the literature) on GLP-1 RAs licensed in South Asia or under regulatory approval in one or more South Asian countries is presented and based on prescription pattern and the geography of the reported patient group. In an evidence-based approach, the key points contributing to this consensus with respect to the clinical impact and benefits of GLP-1 RAs and their use in special populations are as follows:

Clinical impact of GLP-1 RAs:GLP-1 RAs improve glucose homeostasis by enhancing glucose-dependent insulin secretion, by suppressing inappropriately elevated glucagon levels, both in fasting and postprandial states (Grade A; Evidence Level \[EL\] 1).GLP-1 RAs are associated with weight loss benefits which might be due to suppressed appetite, reduced body fat or improved endothelial function (Grade A; EL 1).GLP-1 RAs are known to have a beneficial effect on lipid profile and blood pressure (BP). In addition, GLP-1 RAs have demonstrated cardioprotective effects in patients with T2DM (Grade A; EL 1).GLP-1 RAs are known to have both direct and indirect renoprotective effects and are also associated with hepatic health benefits (Grade A; EL 1).

GLP-1 RA use in complicated diabetes:There is no clear evidence regarding the use of GLP-1 RA in acute myocardial infarction, although the use of these agents is encouraged in patients with asymptomatic and stable coronary artery disease (CAD). The use of GLP-1 analogues in such cases could be a pragmatic approach based on prescribing information, available clinical evidence and clinical sense of physicians (Grade D; EL 4)Exenatide and lixisenatide are predominantly cleared by the kidney. Exenatide dosage is not recommended to be increased in patients with an estimated glomerular filtration rate (eGFR) of 30--60 mL/min/1.73 m^2^. Both exenatide and lixisenatide are contraindicated in patients with eGFR \< 30 mL/min/1.73 m^2^. Although clearance of liraglutide and dulaglutide is predominantly hepatic, administration of these drugs in patients with renal impairment needs to be considered with caution because of gastrointestinal side effects (Grade D; EL 4).There is limited information available on the safety and efficacy of GLP-1 RAs in patients with hepatic impairment. The prescribing information advises cautious use in this patient population (Grade D; EL 4).

GLP-1 RA use in special situations:GLP-1 RAs are known to have low risk of hypoglycaemia and offer least glycaemic variability which is suitable for the elderly population (Grade B; EL 2).GLP-1 RAs do not require dose adjustments during fasting including the period of Ramadan; however, dose adjustments for concomitant medications such as insulin may be required (Grade D; EL 4).GLP-1 RAs have expanded the treatment option for polycystic ovary syndrome owing to their ability to influence both body weight and glycaemic control (Grade A; EL 1).There is limited data on the use GLP-1 RAs in pregnant and lactating women (Grade D; EL 4).

Based on the experience, judgement and consensus of the expert panel of endocrinologists, essential information on GLP-1 RA therapy for healthcare practitioners in the form of checklists has been presented. The checklists include patient selection and rationale for GLP-1 RA therapy initiation, factors influencing selection of appropriate GLP-1 RA, selection of appropriate GLP-1 RA and monitoring checklist specific for GLP-1 RA-based therapy. Cost implications, barriers to GLP-1 RA therapy and measures to mitigate the barriers have also been discussed.

Introduction {#Sec2}
============

Type 2 diabetes mellitus (T2DM) is the most common type of diabetes, accounting for approximately 90% of all cases worldwide. The global prevalence of diabetes was estimated to be 8.8% (as of 2017) and is foreseen to rise to 9.9% by 2045 \[[@CR1]\]. Among the ethnic groups, people of South Asian ancestry are four times more susceptible to T2DM compared to Europeans owing to their genetic predisposition \[[@CR2]\]. In addition, lifestyle changes including those associated with urbanisation and migration play a major role in the rapid rise of diabetes in South Asia \[[@CR3]\]. Notably, India and Pakistan are listed among the top 10 countries worldwide for the number of adults (age group 20--79 years) with diabetes \[[@CR1]\]. The prevalence of diabetes and the mortality and expenditure associated with it in South Asia (as of 2017) are presented by country in Table [1](#Tab1){ref-type="table"}.Table 1Prevalence, mortality and expenditure associated with diabetes burden in South Asian countries.Adapted from IDF Diabetes Atlas, 8th Edition \[[@CR4]\]CountryTotal adult population^a^Diabetes cases^a^Ratio^a,b^Undiagnosed diabetes cases^a^Diabetes national prevalence^a^ (%)Diabetes age-adjusted comparative prevalence^a^ (%)Diabetes-related death^a^Cost per person with diabetes (USD)Afghanistan17,150,8141,054,4601:16733,8706.19.220,960114.67Bangladesh108,274,0407,349,5261:154,115,7346.88.3108,53050.94India892,039,24074,047,2661:1242,847,3348.39.81,123,804120.07Maldives254,70218,9961:1310,3197.58.91281939.74Nepal18,141,114679,2071:27549,9343.77.113,43174.18Pakistan116,776,5567,656,3171:154,706,3386.68.089,28563.23Sri Lanka14,922,2521,248,3101:12446,6458.410.317,747189.63^a^Age group 18--99 years^b^Total number of diabetes cases: total adult population

Obesity is identified as a major risk factor leading to diabetes, hypertension, dyslipidaemia, coronary heart disease and many types of cancers \[[@CR5]\]. The mean prevalence of obesity in South Asia rose to 28.85% in 2013 from 23.62% in 1990, drawing attention to the seriousness of this growing public health issue \[[@CR6]\]. The thin-fat Indian concept or Asian Indian phenotype is characterised by less generalised obesity measured by body mass index (BMI) and greater central obesity associated with waist circumference and waist--hip ratio \[[@CR7]--[@CR9]\]. Higher prevalence of central obesity among South Asians is also considered to be an important risk factor for T2DM, metabolic syndrome (MetS) and cardiovascular disease (CVD) \[[@CR10], [@CR11]\]. Nutritional transition, urbanisation, physical inactivity, socio-economic factors, cultural factors and genetics are currently the determinants of obesity and dyslipidaemia in South Asians \[[@CR10]\].

The term diabesity, first coined in 1970, has been used to describe the strong association between diabetes and obesity when they co-exist in an individual \[[@CR12], [@CR13]\]. At least 80--90% of T2DM patients are reported to be obese \[[@CR14], [@CR15]\]. Diabesity is expected to be one of the biggest epidemics in human history. Intriguingly, there are no guidelines from associations worldwide for the optimal management of diabesity to date \[[@CR12], [@CR16]\].

The therapeutic armamentarium for management of T2DM ranges from the conventional oral antidiabetic (OAD) medications and insulin therapy along with lifestyle modifications to the newer class of drugs including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose co-transporter-2 (SGLT2) inhibitors. SGLT2 inhibitors are a class of OADs that function by reducing renal tubular glucose reabsorption, thereby reducing blood glucose without stimulating insulin release \[[@CR17]\].

GLP-1 RAs are a class of injectable drugs used for the management of T2DM. Currently, few drugs in this class are approved globally, and the rest are at various stages of approval. GLP-1 RAs aid in glycaemic control through multiple mechanisms. In a glucose-dependent mechanism, GLP-1 RAs stimulate insulin secretion and suppress inappropriately elevated glucagon levels. These drugs are known to delay gastric emptying and promote satiety and are associated with a reduced risk of hypoglycaemia \[[@CR18]--[@CR21]\]. Accordingly, GLP-1 RAs can be considered as calorie restriction mimetics or calorie restriction facilitators. Furthermore, these drugs aid in modest weight loss unlike the weight gain typically observed with some of the antidiabetic medications and are being explored for their potential to address all components of MetS including obesity, hypertension, dyslipidaemia, polycystic ovary syndrome (PCOS) and fatty liver \[[@CR22]--[@CR24]\].

Diabetes associations across the globe have been formulating and updating guidelines on GLP-1 RAs in T2DM management to optimise and provide targeted treatment for the effective use of this class of agents. As there remains a gap in guidance towards GLP-1 RA therapy in the South Asian region, this report attempts to address any issues or specific guidance to real-world healthcare practitioners (HCPs) in order to manage T2DM using GLP-1 RAs in this geography.

The objective of this report is to develop a consensus for the use of GLP-1 RAs in the management of T2DM in the South Asian population based on a pragmatic review of clinical evidence and insights from experts representing India, Pakistan, Bangladesh, Nepal, Sri Lanka, Afghanistan and the Maldives. In addition, this report provides an objective snapshot of consensus practices for HCPs among the participating countries regarding the characteristics of ideal GLP-1 RA candidates, timing of therapy initiation, parameters to be monitored during therapy, use in special populations, cost implications, management of adverse events (AEs) and strategies to combat multidimensional barriers to support adherence to GLP-1 RA therapy.

Current Approval Status of GLP-1 RAs in South Asia {#Sec3}
--------------------------------------------------

The approval status of GLP-1 RAs in the participating South Asian countries is presented in Table [2](#Tab2){ref-type="table"}. Other GLP-1 RAs, namely albiglutide QW, exenatide QW and semaglutide QW, approved by the US Food and Drug Association (USFDA), are currently not available in the South Asian market and are in approval stages in South Asia. However, none of the GLP-1 RAs have been listed in the national list of essential medicines in any of the South Asian countries to date.Table 2Current approval status of GLP-1 RAs in South AsiaGLP-1 RAApproval in participating countriesAfghanistanBangladeshIndiaMaldivesNepalPakistanSri LankaDulaglutide (QW)✔✔✔Exenatide (BID)✔✔Liraglutide (QD)✔✔✔✔✔Lixisenatide (QD)✔*GLP*-*1 RA* glucagon-like peptide-1 receptor agonist

Methodology {#Sec4}
===========

This report is based on a review of published guidelines and clinical evidence from meta-analyses, systematic reviews, randomised controlled trials, prospective and retrospective studies, and real-world data on GLP-1 RA use in the management of T2DM. Conference abstracts were not included for this report. The consensus was developed in accordance with the American Association of Clinical Endocrinologists' protocol \[[@CR25]\]. Recommendations were based on clinical importance coupled with four intuitive levels of evidence as presented in Table [3](#Tab3){ref-type="table"}. In case of little or no evidence, the panel relied on logical empiricism, judgement and consensus to make the recommendations. The panellists of the consensus were endocrinologists representing South Asian countries including India, Pakistan, Bangladesh, Nepal, Sri Lanka, Afghanistan and the Maldives. This report was developed following a preliminary consensus meeting held in New Delhi, India on 2 June 2018, followed by another meeting held in Colombo, Sri Lanka, on 1 September 2018. These meetings were sponsored by Eli Lilly, India, and were organized under the auspices of the steering committee. The sponsor had no formal voting during the consensus, and had no influence on the development of consensus statements or this manuscript.Table 3Evidence and recommendation grading according to the American Association of Clinical Endocrinologists' guidelinesEvidence levelSemantic descriptor (reference methodology)GradesRecommendation1Meta-analyses of RCTs, RCTsAStrong2Meta-analyses of non-randomised prospective or case-controlled trials, non-RCT, prospective cohort study, retrospective case-control studyBIntermediate3Cross-sectional study, surveillance study (registries, surveys, epidemiologic study, retrospective chart review, mathematical modelling of database), consecutive case series, single case reportsCWeak4No evidence (theory, opinion, consensus, review or preclinical study)DNo evidence*RCTs* randomised controlled trials

Compliance with Ethics Guidelines {#Sec5}
---------------------------------

This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

Rationale {#Sec6}
=========

The incretin system or incretin hormones principally include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which are released by the gut endocrine cells in response to meal intake \[[@CR26]\]. GLP-1 lowers blood glucose through stimulation of insulin secretion (and production) and suppression of glucagon secretion in a glucose-dependent manner \[[@CR22]\]. GLP-1 is a pluripotent incretin hormone in humans which exerts multiple physiological actions, and the main targets of GLP-1 and its actions are depicted in Fig. [1](#Fig1){ref-type="fig"} \[[@CR27]\].Fig. 1GLP-1 target organs and its action.*GLP-1* glucagon-like peptide-1,*VLDL* very low density lipoprotein

The incretin hormones may be responsible for up to 70% of postprandial insulin secretion. Their effects are progressively amplified from the beginning of a meal in response to increase in plasma glucose concentrations. The incretin effect is severely reduced or absent in patients with T2DM. Impaired incretin effect in T2DM could be due to impaired incretin hormone secretion (incretin hormone deficiency) and/or defective insulinotropic action of the incretin hormones (incretin hormone resistance). Despite controversies in the literature, the data indicate the impaired incretin effect in patients with T2DM to be associated with defective insulin secretory effects of GIP and GLP-1 as opposed to defective secretion of the incretin hormones \[[@CR28]\]. In the case of GLP-1, their secretion in patients with T2DM is impaired; however, the insulinotropic and glucagon-suppressive actions are preserved. This forms the rationale for incretin-based therapy in T2DM \[[@CR26]\].

Interestingly, the point of action of GLP-1 RAs extends beyond β-cells, and these agents effectively act on the cells of the islets of Langerhans as a whole to bring in equilibrium in both pre-diabetic and diabetic conditions as illustrated in an islet-centric fulcrum (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Islet-centric fulcrum for GLP-1 RA-based therapy.*GLP-1 RA* glucagon-like peptide-1 receptor agonist,*T2DM* type 2 diabetes mellitus

Exogenous GLP-1 administration may restore blood glucose regulation to near normal levels in patients with T2DM whose incretin effect is reduced \[[@CR26]\]. GLP-1 RAs or incretin mimetics are agonists of the GLP-1 receptors. GLP-1 RAs possess pleiotropic effects similar to endogenous GLP-1 \[[@CR29], [@CR30]\].

Mechanism of Action of GLP-1 {#Sec7}
============================

GLP-1 elicits protracted glucose-lowering in a glucose-dependent manner owing to its insulinotropic mechanism of action in pancreatic β-cells. In contrast, its non-insulinotropic action is marked by extra-pancreatic effects which might be beneficial for the prevention and treatment of diabetes‐related complications and comorbidities presented independently of glycaemic control.

Insulinotropic Mechanism of Action {#Sec8}
----------------------------------

The insulinotropic activity of GLP-1 is (at least) partly exerted through interaction with the GLP-1 receptors located on the cell membrane of the β-cells. Figure [3](#Fig3){ref-type="fig"} depicts the molecular mechanisms underlying the insulinotropic effects of GLP-1 along with a brief summary of the mechanism of action \[[@CR31], [@CR32]\].Fig. 3Molecular mechanisms underlying insulinotropic effects of GLP-1. Binding of GLP-1 to GLP-1 receptors leads to the activation of adenylate cyclase and elevation of intracellular cAMP levels. Increased cAMP levels subsequently activate PKA and the cAMP-regulated guanine nucleotide exchange factor II (cAMP-GEFII, also known as Epac2). Activation of PKA leads to the closure of K~ATP~ channels, thereby facilitating membrane depolarisation (1). PKA activation also leads to the inhibition of delayed rectifying K^+^ (K~v~) channels, which is a negative regulator of insulin secretion in pancreatic β-cells, thus resulting in prolongation of action potentials (2). Depolarisation results in the opening of voltage-gated Ca^2+^ channels, leading to an increase in intracellular Ca^2+^ concentrations (3). Increased intracellular Ca^2+^ concentrations mobilise Ca^2+^ from intracellular stores through PKA- and Epac2-dependent mechanisms (4). The increased Ca^2+^ concentration leads to the events as follows: insulin-containing granules fuse with the plasma membrane and insulin is secreted from β-cells (5); Ca^2+^-induced Ca^2+^ mobilisation from intracellular stores stimulates ATP synthesis in mitochondria which further enhances membrane depolarisation through K~ATP~ channel closure (6); Transcription of the proinsulin gene is promoted (7); Activation of EPAC2 also increases the density of insulin-containing granules near the plasma membrane to potentiate insulin secretion from β-cells (8).*cAMP* cyclic adenosine monophosphate,*GLP-1* glucagon-like peptide-1,*PKA* protein kinase A

Non-Insulinotropic Actions of GLP-1 {#Sec9}
-----------------------------------

Suppression of glucagon expression by GLP-1 is considered to be clinically important as GLP-1 loses its inhibitory effect on glucagon secretion at hypoglycaemic levels. However, there is uncertainty around the mechanism whereby this occurs \[[@CR33], [@CR34]\]. GLP-1 inhibits meal-induced acid secretions, gastric emptying, gastrointestinal (GI) motility and pancreatic secretions. The effects of GLP-1 on gastric functions are mediated through vagal pathways \[[@CR31], [@CR35]\].

GLP-1 influences feeding behaviour and body weight both through direct (by entering the brain via the systemic circulation and by crossing the blood--brain barrier) and indirect pathways (via neural afferents) which are largely mediated by the central nervous system. Evidence from preclinical data demonstrates that central GLP-1 induces satiety by affecting both homeostatic and reward-associated food intake, and such effects seem to be mediated by the GLP-1 receptor \[[@CR36]\].

GLP-1 aids in β-cell proliferation and survival. An increase in β-cell mass and decrease in apoptotic β-cells were demonstrated in several animal studies \[[@CR37], [@CR38]\]

Classification of GLP-1 RAs {#Sec10}
===========================

On the basis of the duration of action, GLP-1 RAs can be classified as short-acting, intermediate-acting, long-acting and continuous-acting GLP-1 RAs (Table [4](#Tab4){ref-type="table"}). The differences between short-acting and long-acting GLP-1 RAs in terms of their effectiveness on several physiological parameters are presented in Table [5](#Tab5){ref-type="table"} \[[@CR39]\].Table 4Classification of GLP-1 RAsClassificationCompoundHalf-lifeShort-actingExenatideLixisenatide\< 12 hIntermediate-actingLiraglutide12--24 hLong-actingExenatide LARAlbiglutideSemaglutide\> 24 h to 1 monthContinuous-actingITCA 650^a^\> 1 month*GLP*-*1 RA* glucagon-like peptide-1 receptor agonist, *LAR* long-acting release^a^ITCA 650 is an investigational drugTable 5Comparison between short-acting and long-acting GLP-1 RAsParametersShort-acting GLP-1 RAsLong-acting GLP-1 RAsEffects Fasting blood glucose levelsModest reductionStrong reduction Postprandial hyperglycaemiaStrong reductionModest reduction Fasting insulin secretionModest stimulationStrong stimulation Postprandial insulin secretionReductionModest stimulation Glucagon secretionReductionReduction Gastric emptying rateDecelerationNo effect Blood pressureReductionReduction Heart rateNo effect or small increase (0--2 bpm)Moderate increase (2--5 bpm) Body weight reduction1--5 kg2--5 kg Occurrence of nausea20--50%, attenuates slowly (weeks to many months)20--40%, attenuates quickly (\~ 4--8 weeks)*GLP*-*1 RA* glucagon-like peptide-1 receptor agonist

Short-Acting GLP-1 RAs {#Sec11}
----------------------

Short-acting GLP-1 RAs provide short-lived GLP-1 receptor activation. Although resistant to dipeptidyl peptidase-4 (DPP4), GLP-1 RAs have a plasma half-life of about 2--4 h and are eliminated through the renal system. Short-acting GLP-1 RAs primarily lower postprandial blood glucose (PPBG) levels through delayed gastric emptying because of which the rate of glucose entry into the duodenum and subsequently into the circulation is delayed \[[@CR22], [@CR39]\].

Intermediate-Acting GLP-1 RAs {#Sec12}
-----------------------------

The intermediate-acting GLP-1 RAs liraglutide is an acylated GLP-1 RA that exhibits a prolonged half-life of 13 h. Liraglutide is endogenously metabolised in a similar manner to large proteins without a specific organ as a major route of elimination \[[@CR40]\].

Long-Acting GLP-1 RAs {#Sec13}
---------------------

Long-acting GLP-1 RAs keep activating the GLP-1 receptors continuously at the recommended doses. Long-acting GLP-1 RAs lower blood glucose primarily by stimulating insulin secretion and reducing glucagon levels. Greater reductions in plasma glycated haemoglobin (HbA1c) are observed with long-acting GLP-1 RAs compared to short-acting GLP-1 RAs due to their consistently high plasma levels. The reduction in body weight with long-acting GLP-1 RAs is comparable to those with short-acting GLP-1 RAs \[[@CR39]\].

Continuous-Acting GLP-1 RA (Implantable GLP-1 RAs) {#Sec14}
--------------------------------------------------

A miniature implantable GLP-1 RA, ITCA 650, is hereby classified as a continuous-acting GLP-1 RA. ITCA-650, with an osmotic pump system, delivers zero-order continuous subcutaneous exenatide at a precise, pre-set rate for up to 12 months. Although an invasive therapy, ITCA 650 is advantageous in terms of injection frequency and effort needed from the patient. However, uncertainty about the usefulness of the therapy during illness, fasting or sudden change in the renal/hepatic parameters is considered one of the limitations \[[@CR41]\].

Pharmacokinetics and Pharmacodynamics of GLP-1 RAs {#Sec15}
==================================================

The GLP-1 RAs are administered weekly to twice daily according to the formulation. The pharmacokinetics and pharmacodynamics of this class of drugs are presented in Tables [6](#Tab6){ref-type="table"} and  [7](#Tab7){ref-type="table"}, respectively.Table 6Pharmacokinetics of GLP-1 RAsFunctionParametersDulaglutide QW \[[@CR42]\]Exenatide BID \[[@CR43]\]Exenatide QW \[[@CR44]\]Liraglutide QD \[[@CR45], [@CR46]\]Lixisenatide QD \[[@CR47]\]Semaglutide QW \[[@CR48]--[@CR51]\]Absorption*C* ~max~114 ng/mL211 pg/mL (10 µg)137.3 pg/mL35 ng/mL (0.6 mg)56.7 pg/mL (10 µg)10.9 nmol/L (0.5 mg)AUC14,000 ng h/mL1036 pg h/mL (10 µg)405.6 pg h/mL960 ng h/mL (0.6 mg)175 pg h/mL (5 µg), 365 pg h/mL (10 µg), 503 pg h/mL (20 µg)3123.4 nmol h/L (0.5 mg)Steady stateWithin 2 and 4 weeksNA9--10 weeks4 daysNA4--5 weeksDistributionVolume of distributionFor 0.75 mg, 19.2 L. For 1.5 mg, 17.4 L28.3 L28.3 L13 L, after SC administration (0.6 mg), 0.07 L/kg (after IV) (0.6 mg)90--140 L12.5 LMetabolismMetabolic pathwayGeneral protein catabolism pathwayGlomerular filtration and proteolytic degradationGlomerular filtration with proteolytic degradationNo specific organ as a major route of elimination. Excreted as related metabolites in urine or faeces (6% and 5%, respectively)Presumed to be eliminated through glomerular filtration, tubular reabsorption and metabolic degradation resulting in smaller peptides reintroduced in protein metabolismProteolytic cleavage of the peptide backbone and sequential beta-oxidation of fatty acid side chainEliminationClearanceFor 0.75 mg, 0.111 L/h. For 1.5 mg, 0.107 L/h9.1 L/h9.1 L/h20--67 L/h35 L/h0.05 L/hElimination half-life5 days2.4 hMedian half-life, 2 weeks (2 mg)13 h1.5--4.5 h1 week*AUC* area under the curve, *C*~*max*~ maximum concentration achieved before the administration of second dose, *GLP*-*1 RA* glucagon-like peptide-1 receptor agonist, *NA* not available, *SC* subcutaneousTable 7Pharmacodynamics of GLP-1 RAsGLP-1 RAEffect on insulin secretionEffect on glucagon secretionEffect on GI motilityElectrophysiological effectDulaglutide QW \[[@CR42]\]Increase in 1st and 2nd phase insulin secretionReduces fasting glucagon concentration by 1.71 and 2.05 pmol/LCauses a delay in gastric emptying (the delay is largest with the first dose and diminishes with subsequent doses)Does not prolong QTc^a^ interval (at supra-therapeutic doses of 4 mg and 7 mg)Exenatide BID \[[@CR43]\]Increase in 1st and 2nd phase insulin secretionModerates glucagon secretions and lowers serum concentrations during periods of hyperglycaemiaDelays gastric emptyingNot associated with clinically meaningful prolongation of QTc intervalExenatide QW \[[@CR52]\]1st and 2nd phase insulin secretion enhancementModerates glucagon secretion and lowers glucagon concentration during periods of hyperglycaemiaSlows gastric emptyingNot associated with prolongation of QTcLiraglutide QD \[[@CR45], [@CR52]\]1st and 2nd phase of insulin secretion enhancementLowers glucagon secretion. Does not impair normal glucagon response to low glucose concentrationsDelays gastric emptyingDoes not produce QTc interval (up to 1.8 mg)Lixisenatide QD \[[@CR47], [@CR53]\]Resensitisation of 1st phase insulin secretion and increase in 2nd phase insulin secretionGlucagon secretion is suppressedSlows gastric emptyingThere was no mean increase in QTc even at supra-therapeutic dosesSemaglutide QW \[[@CR48]\]Increase in 1st and 2nd phase insulin secretionLowers fasting and postprandial glucagon concentrationsDelays early postprandial gastric emptyingDoes not prolong QTc interval to any clinically relevant extent (1.5 times the recommended dose)*GI* gastrointestinal, *GLP*-*1 RA* glucagon-like peptide-1 receptor agonist^a^QTc: in electrocardiography, the duration of the QT interval adjusted for the patient's heart rate

Overview of Prescribing Information/Package Insert of GLP-1 RAs in South Asia {#Sec16}
=============================================================================

An overview of the prescribing information/package insert of GLP-1 RAs pertaining to all GLP-1 RAs approved in South Asia as well as the ones to be launched in the near future is provided in Table [8](#Tab8){ref-type="table"} with a brief summary as follows.Table 8Overview of the prescribing information/package insert of GLP-1 RAs in South AsiaIndications \[[@CR42]--[@CR45], [@CR47], [@CR48], [@CR54]\]Contraindications/limitations \[[@CR42]--[@CR45], [@CR47], [@CR48], [@CR54]\]Warnings and precautions \[[@CR42]--[@CR45], [@CR47], [@CR48], [@CR54]\]As an adjunct to diet and exercise in adults with T2DM. Recommended as monotherapy in a few countries (e.g. dulaglutide in India). Indicated in adults (liraglutide) with established CVD to reduce the risk of major adverse CV eventsPersonal or family history of MTC or in patients with MEN2. Prior serious hypersensitivity. Not to be used in T1DM or diabetic ketoacidosis. Lack of data in patients with pancreatitisRisk of MTC. Pancreatitis---to be discontinued promptly. Hypoglycaemia--- reduction of doses of concomitant medications. Renal impairment---patients reporting severe GI adverse events. Hypersensitivity. Not recommended in patients with severe GI diseases*CV* cardiovascular, *CVD* cardiovascular disease, *GI* gastrointestinal, *GLP*-*1 RA* glucagon-like peptide-1 receptor agonist, *MEN2* multiple endocrine neoplasia type 2, *MTC* medullary thyroid carcinoma, *T1DM* type 1 diabetes mellitus, *T2DM* type 2 diabetes mellitus

GLP-1 RAs including dulaglutide, exenatide BID, liraglutide, lixisenatide and semaglutide are indicated in adults with T2DM as an adjunct to diet and exercise to improve glycaemic control. Dulaglutide is even recommended as monotherapy in India. In addition to glycaemic control, liraglutide has been indicated in adults with established CVD to reduce the risk of major adverse cardiovascular events. GLP-1 RAs are contraindicated in patients with prior hypersensitivity to the respective drug or any product components, personal or family history of medullary thyroid carcinoma (MTC) or in patients with multiple endocrine neoplasia syndrome type 2 (MEN2). These GLP-1 RAs are not to be used in the treatment of type 1 diabetes mellitus or diabetes ketoacidosis. In case of suspected pancreatitis, GLP-1 RAs are to be discontinued and should not be restarted if pancreatitis is confirmed.

A detailed description on the use of GLP-1 RA in special populations and AEs common for GLP-1 RAs is given in the following sections.

Overview of GLP-1 Ra Recommendations for T2DM Management from Diabetic Associations Across the World {#Sec17}
====================================================================================================

Diabetes, a chronic and complex condition, demands continuous and individualised care with a multipronged approach. Diabetes management is comprehensive and extends beyond glycaemic control in T2DM patients, often taking into consideration other comorbidities associated with the condition \[[@CR55], [@CR56]\].

Guidelines for the management of diabetes intend to provide evidence-based recommendations to physicians across the world for diagnosis, management and follow-up \[[@CR57]\]. Consequently, guidelines provide a comprehensive picture and awareness to the practitioner to confront the situation effectively.

A study conducted in the USA reported that a periodic evaluation of HbA1c and lipid profile as recommended by the guidelines had resulted in a significant decrease in the rates of hospitalisation due to vascular, renal and other diabetes-related complications \[[@CR58]\].

Table [9](#Tab9){ref-type="table"} summarises the key points on the recommendation of GLP-1 RAs in T2DM management from selected diabetic associations across the world.Table 9Overview of recommendations from diabetes associations across the world for the use of GLP-1 RAs in T2DM managementAssociation/countryTop recommendations on the use of GLP-1 RAs^a^Comments (if any)AACE/ACE \[[@CR59]\]Pre-diabetes  To be considered with caution along with lifestyle therapy if glycaemia is not normalised with low-risk medications such as metformin and acarboseHbA1c \< 7.5%  Recommended as monotherapy for patients with recent-onset T2DM or mild hyperglycaemia along with lifestyle therapyHbA1c \> 7.5%  Recommended in dual therapy along with metformin or another first-line agent along with lifestyle therapy  Recommended in triple therapy along with metformin or other first-line agent and second-line agent along with lifestyle therapyHbA1c \> 9%  For patients without symptoms^c^, GLP-1 RA is recommended in dual therapy or triple therapy  For patients with symptoms, insulin with or without other agents is recommended along with lifestyle therapyThe observational window to achieve glycaemic goal in each stage, i.e. mono-, dual and triple therapy, during progression of disease is 3 months. If the goals are unmet, the therapy should be escalated to next phase and/or insulin should be added or intensified as required^b^ADA/EASD \[[@CR60]\]In dual therapy along with metforminIn triple therapy along with metformin and SU, TZD or insulinIn combination injectable therapy with metformin and basal insulin--Non-insulin antidiabetic pharmacotherapy in patients with established CVD: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy \[[@CR61]\]A few SGLT2i (empagliflozin and canagliflozin) and GLP-1 RAs (liraglutide and semaglutide) reduced CV events in adequately powered studies with contemporary concomitant CV treatment in patients with established CVD (mainly stable CHD with the exclusion of recent ACS) and hence may be considered as the preferred treatment choiceWhen the aforementioned preferred treatments (with selected SGLT2i and GLP-1 RA) are not sufficient to achieve therapeutic goals or are contraindicated, agents such as thiazolidinedione-pioglitazone, GLP1 RA-exenatide and dipeptidyl peptidase inhibitors which have established neutral or potentially beneficial effects on CV events in adequately powered, contemporary trials may be preferredAntidiabetic pharmacotherapy should be chosen on the basis of beneficial effects on CV events in phase 3 and post-marketing trials and as per EMA; improvement of glycaemic control and reduction of CV morbidity and mortality should be major goals in the treatment of T2DMIDF \[[@CR62]\]In dual therapy if weight loss is a priority and if the drug is affordableIn triple therapy instead of basal insulin along with 2 glucose-lowering drugs if weight loss has been insufficientPatients should not remain longer than 3 to 6 months with HbA1c above target before adding a second glucose-lowering drugNICE \[[@CR63]\]In combination with metformin and SU if triple therapy with metformin and 2 other OADs is not effective, not tolerated or contraindicatedContinued only if the person with T2DM has had a beneficial metabolic response (a reduction of at least 1% in HbA1c and a weight loss of at least 3% of initial body weight in 6 months)In combination with insulin, only with specialist care advice and ongoing support from a consultant-led multidisciplinary team--RSSDI \[[@CR64]\]As an add-on to metformin in obese T2DM patients in addition to lifestyle changesAs second-line or third-line option for the management of uncontrolled hyperglycaemiaAs second-line therapy in overweight/obese patients with metformin inadequacy and as first-line therapy in patients with metformin intoleranceAs an add-on to insulin therapy if glycaemic goals are unmet with reasonably high doses of insulin or if unacceptable weight gain or hypoglycaemia occursGLP-1 RAs with proven CV benefit, e.g. liraglutide, should be considered to reduce the risk of major adverse CV eventsDEAN \[[@CR65]\]As a third-line agent to metformin (+ lifestyle modification) and SU/DPP4 inhibitor/α-glucosidase inhibitor if glycaemic target is not achieved in 2 monthsPakistan Endocrine Society \[[@CR66]\]For initial fasting plasma glucose of 200--300 mg/dL  GLP-1 RA is added as a third drug to metformin and OADs like SU, DPP4i and pioglitazone if glycaemic target is not achieved at 6 months with OADs (metformin, SU, DPP4i and pioglitazone) and lifestyle modifications  GLP-1 RA is considered as an add-on to insulin regimen if glycaemic target is not achieved at 9 monthsFor initial fasting plasma glucose of \> 300 mg/dL  GLP-1 RA is considered as a part of triple therapy with metformin and other OADs like SU/DPP4i/pioglitazone or basal insulin if glycaemic target is not achieved at 3 months  GLP-1 RA is considered as an add-on to insulin regimen if glycaemic target is not achieved at 9 monthsEndocrine Society of Sri Lanka \[[@CR67]\]As a first-line medication if metformin is not tolerated or contraindicatedAs a second-line agent to lifestyle modification ± metformin if glycaemic target is not achieved in 3 months and as a third agent to lifestyle modification ± metformin and oral antidiabetics if glycaemic target is not achieved in 6 months*AACE* American Association of Clinical Endocrinologists, *ACE* American College of Endocrinology; *ACS* acute coronary syndrome, *ADA* American Diabetes Association, *CHD* coronary heart disease, *CV* cardiovascular, *CVD* cardiovascular disease, *DEAN* Diabetes and Endocrinology Association of Nepal, *DPP4i* dipeptidyl peptidase-4 inhibitor, *EASD* European Association for the Study of Diabetes, *EMA* European Medicines Agency, *GLP*-*1 RA* glucagon-like peptide-1 receptor agonist, *HbA1c* glycated haemoglobin, *IDF* International Diabetes Federation, *NICE* National Institute for Health and Care Excellence, *OAD* oral antidiabetic drug, *RSSD* Research Society for the Study of Diabetes in India, *SGLT2i* sodium-glucose co-transporter-2 inhibitors, *SU* sulfonylurea, *TZD* thiazolidinediones, *T2DM* type 2 diabetes mellitus^a^Refer to cited guidelines for detailed information^b^Individualised goals: A1c ≤ 6.5% for patients without concurrent serious illness and at low hypoglycaemic risk; A1c \> 6.5% for patients with concurrent serious illness and at risk of hypoglycaemia progression^c^Typical osmotic or catabolic symptoms of diabetes mellitus

The usefulness of GLP-1 analogues in glycaemic control with low risk of hypoglycaemia and body weight reduction has been taken into consideration in all the guidelines listed in Table [9](#Tab9){ref-type="table"}.

All the guidelines listed in Table [9](#Tab9){ref-type="table"} recommend GLP-1 RAs as a part of dual or triple therapy in combination with OAD drugs with or without insulin in accordance with the respective algorithm \[[@CR55], [@CR59], [@CR60], [@CR62]--[@CR64]\].

In the consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology (AACE/ACE), GLP-1 RA is recommended as monotherapy in individuals with HbA1c \< 7.5%. In addition, GLP-1 RA is recommended in pre-diabetic patients if glycaemia is not normalised with medications such as metformin and acarbose \[[@CR59]\]. AACE/ACE guidelines strive for stringent HbA1c targets (≤ 6.5%) compared to American Diabetes Association--European Association for the Study of Diabetes (ADA/EASD) guidelines which aim for an HbA1c target of 7% \[[@CR68]\].

It is important to note that both ADA/EASD and AACE/ACE guidelines endorse the overall cardiovascular and pancreatic safety of incretin therapies \[[@CR68]\].

Associations like International Diabetes Federation, Research Society for the Study of Diabetes in India and Pakistan Endocrine Society take the aspect of affordability into consideration while recommending GLP-1 RAs \[[@CR62], [@CR69]\].

From a South Asian perspective, countries including Bangladesh do not mention GLP-1 RAs in region-specific guidelines, which limits the prescription of GLP-1 RAs by HCPs in those countries.

Clinical Evidence on GLP-1 RAs Licensed in South Asia {#Sec18}
=====================================================

Efficacy and Safety of GLP-1 RAs (Clinical Trial and Real-World Evidence) {#Sec19}
-------------------------------------------------------------------------

As the proposed consensus on GLP-1 RAs is based on a pragmatic review of clinical evidence and insights from experts across South Asia, pragmatic review relies on detailed and thorough analysis of clinical evidence to draw inferences. The clinical trial programme of GLP-1 RAs licensed or under regulatory approval in one or more South Asian countries is presented in Table [10](#Tab10){ref-type="table"}. The available evidence on the efficacy with respect to glycaemic control and change in body weight and safety (nausea and vomiting) from the studies included in the respective clinical trial programme of the GLP-1 RAs along with a few others including real-world studies is presented according to the prescription pattern (monotherapy or in combination with other oral antidiabetic medications and/or insulin) and further classified on the basis of the geography of the reported patient groups as global, global including South Asia and/or South Asia specific in Supplementary Information. The evidence derived from meta-analyses, systematic reviews and pooled analyses is, however, discussed across multiple sections on clinical impact and special populations. Clinical evidence comparing the efficacy of GLP-1 RAs head-to-head and with other classes of antidiabetic agents such as SGLT2 inhibitors (SGLT2i) is exclusively covered in this section.Table 10GLP-1 RAs clinical trial programmeDulaglutide QWExenatide QWLiraglutide QDLixisenatide QDSemaglutide QWKey clinical trials for GLP-1RAs (phase 3)  AWARD-1AMIGO trialsLEAD-1GETGOAL-MONOSUSTAIN-1  AWARD-2DURATION-1^b^LEAD-2GETGOAL-MONOSUSTAIN-2  AWARD-3DURATION-2LEAD-3JapanSUSTAIN-3  AWARD-4DURATION-3LEAD-4GETGOAL-MSUSTAIN-4  AWARD-5DURATION-4LEAD-5GETGOAL-M-AsiaSUSTAIN-5  AWARD-6DURATION-5^b^LEAD-6GETGOAL-XSUSTAIN-7  AWARD-7DURATION-6GETGOAL-F1SUSTAIN-8^a^  AWARD-8DURATION-7GETGOAL-SSUSTAIN-9^a^  AWARD-9DURATION-8GETGOAL-P  AWARD-10GETGOAL-L  AWARD-11^a^GETGOAL-L-AsiaGETGOAL-Duo-1Cardiovascular outcome trials for GLP-1 RAs  REWIND^a^EXSCEL^c^LEADERELIXASUSTAIN-6*AMIGO* AC2993 diabetes management for improving glucose outcomes (exenatide, 10 µg BID), *AWARD* assessment of weekly administration of LY2189265 in diabetes (dulaglutide, 0.75 mg or 1.5 mg QW), *DURATION* diabetes therapy utilization: researching changes in A1C, weight and other factors through intervention with exenatide QW (extended-release exenatide, 2 mg, once weekly), *ELIXA* evaluation of lixisenatide in acute coronary syndrome (lixisenatide, maximum dose 20 µg per day), *EXSCEL* exenatide study of cardiovascular event lowering trial (exenatide QW, 2 mg), *GETGOAL* GLP-1 agonist AVE0010 in patients with type 2 diabetes mellitus for glycaemic control and safety evaluation (lixisenatide, 20 µg once daily), *GLP*-*1 RA* glucagon-like peptide-1 receptor agonist, *LEAD* liraglutide effect and action in diabetes (liraglutide 1.2 mg or 1.8 mg daily), *LEADER* liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (liraglutide, 1.8 mg QD), *REWIND* researching cardiovascular events with a weekly incretin in diabetes (dulaglutide, 0.75 mg or 1.5 mg QW), *SUSTAIN*-*6* trial to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes (semaglutide, 0.5 mg or 1.0 mg QW)^a^Ongoing^b^Includes for exenatide BID^c^Conducted for exenatide QW

Several head-to-head comparative trials and retrospective studies involving GLP-1 RAs have been conducted and a few pivotal studies with key inferences are presented in Table [11](#Tab11){ref-type="table"}.Table 11Head-to-head comparison of GLP-1 RAsStudyGLP-1 RAs comparedNumber of patientsDurationKey inferencesOdawara et al. \[[@CR70]\]. Phase 3, randomised controlled trialDulaglutide vs. liraglutideDula = 281, Lira = 14152 weeksDulaglutide demonstrated better glycaemic control compared to liraglutideDungan et al. \[[@CR71]\]. Phase 3, randomised, open-label parallel-group study (AWARD-6)Dulaglutide vs. liraglutideDula = 299, Lira = 30026 weeksDulaglutide proven non-inferior to liraglutide for least-squares mean reduction in HbA1c. Safety and tolerability profile were similar to that of liraglutideGhosal and Sinha \[[@CR72]\]. Retrospective real-world observational case note studyLiraglutide vs. dulaglutideDula = 30, Lira = 3013 weeksAddition of GLP-1 RAs to metformin and SGLT2i had meaningful impact on all metabolic parameters. Larger proportion of patients achieved HbA1c \< 7% with liraglutide compared to dulaglutideDrucker et al. \[[@CR73]\]. Randomised, non-inferiority studyExenatide QW vs. exenatide BIDEQW = 148, ExBID = 14530 weeksSignificantly a greater improvement in glycaemic control was demonstrated with EQW compared to ExBID. The body weight reduction was similar between the 2 groupsBlevins et al. \[[@CR74]\]. Randomised, open-label studyExenatide QW vs. exenatide BIDEQW = 129, ExBID = 12324 weeksEQW demonstrated superior glycaemic control with less nausea compared with ExBIDSheu et al. \[[@CR75]\]. Retrospective post hoc analysisExenatide BID vs. exenatide QWExBID: Asian, *n* = 787; White, *n* = 2223; EQW: Asian, *n* = 511; White, *n* = 1104ExBID: 12--30 weeks, EQW: 24--30 weeksAsian patients exhibited significantly greater reductions in HbA1c and PPBG than white patients with ExBIDJi et al. \[[@CR76]\]. Randomised, comparator-controlled, open-label studyExenatide QW vs. exenatide BIDEQW = 340, ExBID = 33826 weeksEQW was superior to ExBID in HbA1c reduction. Weight loss was greater with ExBIDBuse et al. \[[@CR77]\]. Randomised, parallel-group, multinational, open-label trial (LEAD-6)Liraglutide vs. exenatide BIDLira = 233, ExBID = 23126 weeksSignificantly greater improvement in glycaemic control was observed with liraglutide compared to ExBIDBuse et al. \[[@CR78]\]. Open-label, randomised, parallel-group study (DURATION-6)Exenatide QW vs. liraglutide QDEQW = 461, Lira = 45026 weeksA greater reduction in HbA1c was observed with liraglutide compared to EQWFeher et al. \[[@CR79]\]. Real-world, observational studyLiraglutide QD vs. lixisenatide QDLira = 579, Lixi = 21312 monthsTreatment with liraglutide demonstrated better glycaemic control compared to lixisenatideNauck et al. \[[@CR80]\]. Randomised, parallel-group, open-label trialLiraglutide QD vs. lixisenatide QDLira = 202, Lixi = 20226 weeksLiraglutide demonstrated to be more effective in improving glycaemic control compared to lixisenatideStryker et al. \[[@CR81]\]. Real-world observational studyExenatide QW vs. liraglutide QDEQW = 75, Lira = 7512 monthsMore subjects in the EQW arm achieved an HbA1c \< 7% compared to liraglutide arm; however, the baseline HbA1c was lower for the EQW arm (7.9%) compared to liraglutide arm (8.4%)McAdam-Marx et al. \[[@CR82]\]. Retrospective cohort studyExenatide QW vs. liraglutide QDEQW = 808, Lira = 43331 yearHbA1c and weight reductions were similar in EQW- and liraglutide-treated patientsRosenstock et al. \[[@CR83]\]. Randomised, open-label, active-controlled studyLixisenatide vs. exenatide BIDLixi = 318, ExBID = 31624 weeksLixisenatide demonstrated to be non-inferior in HbA1c reduction compared to ExBID. Slightly lower mean weight loss, lower incidence of hypoglycaemia and better gastrointestinal tolerability were demonstrated with lixisenatide compared with ExBIDAhmann et al. \[[@CR84]\]. Phase 3a, open-label, parallel-group randomised controlled trialSemaglutide QW vs. exenatide QWSema = 404, EQW = 40556 weeksSemaglutide was superior to EQW in improving glycaemic control and reducing body weightRefer to Supplementary Information for changes in HbA1c and body weight and information on adverse events*AWARD* assessment of weekly administration of LY2189265 in diabetes (dulaglutide, 0.75 mg or 1.5 mg QW), *Dula* dulaglutide, *ExBID* exenatide BID, *EQW* exenatide QW, *GLP*-*1 RA* glucagon-like peptide-1 receptor agonist, *HbA1c* glycated haemoglobin, *Lira* liraglutide, *Lixi* lixisenatide, *PPBG* postprandial blood glucose, *Sema* semaglutide, *SGLT2i* sodium-glucose co-transporter-2 inhibitor

GLP-1 RAs: Clinical Impact and Benefits {#Sec20}
=======================================

GLP-1 RAs are known for their glycaemic control as well as extra-glycaemic benefits which are elaborated below.

Glycaemia {#Sec21}
---------

GLP-1 RAs improve glucose homeostasis by enhancing glucose-dependent insulin secretion by suppressing inappropriately elevated glucagon levels, both in fasting and postprandial states, and by delaying gastric emptying \[[@CR22]\]. This cumulatively helps in the reduction of HbA1c levels in patients with T2DM. Changes in HbA1c levels due to GLP-1 RA administration from various clinical trials are presented in Supplementary Information. Table [12](#Tab12){ref-type="table"} presents exclusive evidence from key meta-analyses, systematic reviews and pooled studies discussing the impact of GLP-1 RAs on glycaemia.Table 12GLP-1 RAs: clinical impact and benefits on glycaemiaStudy detailsAimHighlights of GLP-1 RA therapyDulaglutide Zhang et al. \[[@CR85]\]. Meta-analysis and systematic review of 12 RCTs with a range of study durations. Duration 12--104 weeksTo assess the clinical efficacy and safety of dulaglutide in patients with T2DMAs monotherapy: Significant reduction in HbA1c and FBG(WMD − 0.68%; 95% CI − 0.95 to − 0.40) (WMD − 0.90 mmol/L; 95% CI − 1.28 to − 0.52), respectively^a^. 17.4% more patients had HbA1c \< 7% with dulaglutide. As add-on intervention with OAM and insulin: Dulaglutide lowered HbA1c (WMD − 0.51%; 95% CI − 0.68 to − 0.35)^b^Exenatide BID Best et al. \[[@CR86]\]. Systematic review and meta-analysis, including 15 retrospective or prospective observational studies of ≥ 100 patients per treatment group from *n* = 381,218 (overall) and *n* = 392,759 (treated with exenatide). Duration \~ 3 years, 9 monthsTo assess the effectiveness of exenatide BID in clinical practice for T2DM patientsSignificant reduction in HbA1c (− 0.4 to − 0.9%) and FBG (− 10 mg/dL). Statistically significant dosage reductions up to 22% in metformin, 66% in TZD or TZD combination therapy, 75% in SU and prandial insulin Sheu et al. \[[@CR75]\]. Retrospective post hoc analysis for exenatide BID 12 weeks and EQ \[*n* = 4625\]. Duration 24 weeksTo evaluate the efficacy and safety of exenatide BID 10 µg (12--30 weeks) and EQW 2 mg (24--30 weeks) in Asian versus white patients with T2DMHbA1c, FBG, and PPBG were significantly reduced from baseline (*P* \< 0.0001) for both groups. For exenatide BID, HbA1c and PPBG (for all meals) reductions were greater in Asians (*P* \< 0.0001 vs. whites). For EQW, post-breakfast and post-lunch excursions were significantly greater in Asians (*P* = 0.0009 and *P* = 0.0189 vs. whites, respectively)Exenatide QW Kayaniyil et al. \[[@CR87]\]. Network meta-analysis and systematic review of 14 RCTs \[*N* = 161\]. Duration 24 ± 6 weeksTo estimate the relative efficacy and tolerability of EQW versus other GLP-1 RAs for the treatment of adults with T2DM inadequately controlled on metforminSignificant HbA1c reduction relative to lixisenatide (20 µg) QD Grimm et al. \[[@CR88]\]. Post hoc analysis of integrated data from DURATION trials (6 randomised, comparator-controlled trials) \[*N* = 1379\]. Duration 24--30 weeksTo evaluate the efficacy, safety and tolerability of EQW in patients with T2DMSignificant reductions in HbA1c and FBG (− 1.4% \[95% CI − 1.5 to − 1.4%\](−36 mg/dL \[95% CI − 38.4 to − 33.8 mg/dL\]), respectively. Significant improvements in glycaemic control and body weight. Minimal hypoglycaemia risk and good tolerabilityLiraglutide Raskin and Mora \[[@CR89]\]. Review of phase 3 trial including 6 randomised LEAD trials \[*N* = 4456\]. Duration 26--52 weeksTo assess the efficacy and safety of liraglutide in terms of glycaemic controlHbA1c reduction by 1.5% from baseline, which was significantly greater than the comparators^c^FBG and PPBG decreased from baseline (up to − 43.2 mg/dL and − 48.6 mg/dL respectively) with liraglutide (1.8 mg) Ostawal et al. \[[@CR90]\]. Systematic review conducted according to the NICE guidance \[*N* = 7413\]. Duration 3 yearsTo assess the real-world clinical effectiveness of liraglutide in T2DM treatmentSignificant HbA1c reductions (− 0.9% to − 2.26%). One-third patients achieved HbA1c of \< 7.0%. NICE composite endpoints^d^ were met in 16.9% to 47.0% of patientsLixisenatide Anderson et al. \[[@CR91]\] Prospective, multinational, randomised, controlled. Duration 12--26 weeksTo evaluate the efficacy and safety profile of lixisenatide 20 µg once daily across the spectrum of patients with T2DM, including patients not treated with antidiabetic agents and those failing on oral agents, and as an adjunct to basal insulin therapyEffectively reduced HbA1c (range − 0.7% to − 1.0%) and PPBG (range -- 3.1 to − 7.96 mmol/L) across various patient types. Main efficacy feature: Ability to decrease 2-h PPBG immediately post injection Schmidt et al. \[[@CR92]\]. Systematic review and meta-analysis including 14 studies (placebo and active comparators) \[*N* = 6156\]. Duration 4--76 weeksTo assess the efficacy and safety of lixisenatide for treating T2DMSignificant reduction in HbA1c (-- 0.52%; 95% CI -- 0.64 to -- 0.39) and 2-h PPBG. (− 4.58 mmol/L; 95% CI − 5.88 to − 3.28), respectively^e^Significantly fewer symptomatic hypoglycaemic events^f^. More effective 2-h PPBG reduction with a better AE profile^g^. Improved HbA1c levels and moderately reduced body weight^e^Semaglutide Shi et al. \[[@CR93]\]. Systematic review and meta-analysis of 9 phase 3 RCTs \[*N* = 9773\]. Duration 30--104 weeksTo evaluate the clinical efficacy and safety of once-weekly semaglutide in patients with T2DMSignificant reduction in HbA1c (WMD − 0.93%, 95% CI − 1.24 to − 0.62, *P* \< 0.001), FBG (WMD − 1.15 mmol/L, 95% CI − 1.67 to − 0.63, *P* \< 0.001) and mean SMPG (WMD − 1.19 mmol/L, 95% CI − 1.68 to − 0.70, *P* \< 0.001)^a^. Higher risk of GI disorders (RR 1.98; 95% CI 1.49--2.62; *P* \< 0.001)^h^Multiple GLP-1 analogues Kim et al. \[[@CR94]\]. Systematic review and meta-analysis with 15 trials \[*n* = 5090, (2703 in treatment groups and 2387 in control groups)\]. Duration ≥ 12 weeksTo compare the HbA1c‐lowering efficacy of GLP-1 RAs between Asian and non‐Asian populations with T2DMHbA1c reduction was reported to be 1.16% (95% CI -- 1.48, -- 0.85) versus -- 0.83% (95% CI − 0.97, − 0.70) for Asian versus non-Asian-dominant studies, respectively. RR for target HbA1c of ≤ 7.0% was more inclined towards Asian-dominant studies \[RR 5.7 (3.8, 8.7)\] than non-Asian-dominant studies (RR 2.8 \[2.4, 3.3\]), respectively Esposito et al. \[[@CR95]\]. Meta-analysis of 25 RCTs \[*N* = 9771; GLP-1 RA treated, 5083; placebo or comparator treated, 4688). Duration 12--52 weeksTo assess the efficacy of exenatide (BID and long-acting release LAR) and liraglutide in achieving HbA1c target of \< 7% in people with T2DMStatistically significant HbA1c reduction was observed; HbA1c \< 7% was achieved in 46% on exenatide, 47% on liraglutide and 63% on exenatide LAR. Higher HbA1c reduction and HbA1c goal attainment for exenatide LAR and liraglutide^i^. More hypoglycaemia cases with exenatide BID, liraglutide and concomitant use of SU Madsbad \[[@CR96]\]. Review including 9 phase 3 head-to-head trials and 1 large phase 2 study \[*N* = 812 received study drug\]. Duration ∼ 6 monthsTo compare the efficacy and safety of 7 GLP-1 RAs in a head-to-head comparisonNotable reductions in HbA1c levels. Liraglutide led to greater HbA1c levels reduction^j^*AE* adverse events, *DURATION* diabetes therapy utilization: researching changes in A1c, weight and other factors through intervention with exenatide QW (extended-release exenatide, 2 mg, once weekly), *EQW* exenatide QW, *FBG* fasting blood glucose, *GI* gastrointestinal, *GLP*-*1 RA* glucagon-like peptide-1 receptor agonist, *HbA1c* glycated haemoglobin (type A1c), *LAR* long-acting release, *LEAD* liraglutide effect and action in diabetes, *NICE* National Institute for Health and Care Excellence, *OAM* oral antihyperglycaemic medication, *PPBG* postprandial blood glucose, *RCTs* randomised controlled trials, *RR* relative risk, *TZD* thiazolidinediones, *T2DM* type 2 diabetes mellitus, *WMD* weighted mean difference^a^Compared to control (placebo, metformin and liraglutide)^b^Compared to control (placebo, sitagliptin, exenatide, liraglutide and glargine)^c^Sitagliptin (− 0.9%), glimepiride (− 0.5%), rosiglitazone − 0.4%), insulin glargine (− 1.1%) and exenatide (− 0.8%)^d^HbA1c reduction \> 1% and weight reduction ≥ 3%^e^Compared to placebo^f^Compared to other incretin mimetics^g^Compared to exenatide and liraglutide^h^Compared to other therapies^i^Compared to comparator drugs^j^Compared to exenatide formulations and albiglutide

Body Weight and Composition {#Sec22}
---------------------------

GLP-1 RA decreases gastrointestinal motility and hence increases the time for nutrient absorption. It promotes satiety and resting metabolic rate and lowers plasma concentrations of free fatty acids \[[@CR97]\]. It is hypothesised that the weight loss benefits associated with GLP-1 RAs are likely to be due to suppressed appetite, reduced body fat and improved endothelial function \[[@CR98]\]. Changes in body weight due to GLP-1 RA administration from various clinical trials are presented in Supplementary Information. Table [13](#Tab13){ref-type="table"} presents the effect of GLP-1 RAs on body weight and waist circumference from meta-analyses, systematic reviews and pooled studies. In addition, studies comparing the treatment with GLP-1 RA, SGLT2i and bariatric surgery are also presented in Table [13](#Tab13){ref-type="table"}.Table 13GLP-1 RAs: clinical impact and benefits on body weight and compositionStudy detailsAimHighlightsDulaglutide Umpierrez et al. \[[@CR99]\]. Pooled analysis of 6 head-to-head WARD RCTs \[*N* = 5171; dulaglutide 1.5 mg, *n* = 1718; dulaglutide 0.75 mg, *n* = 1417\]. Duration 26--104 weeksTo evaluate the relationship between changes in body weight and HbA1c levelsAt 26 weeks, patients with weight loss: 57--88% (1.5 mg), 43--84% (0.75 mg). Patients with weight loss and HbA1c reductions: 55--83% (1.5 mg), 41--79% (0.75 mg) Yajima et al. \[[@CR100]\]. Prospective study \[*N* = 21; dulaglutide, *n* = 11; teneligliptin, *n* = 10\]. Duration 11 months with follow-up of 6 monthsTo evaluate the effect of dulaglutide QW on body composition in T2DM patients undergoing HDTeneligliptin group: No change. FM (15.7 kg to 14.1 kg, *P* = 0.63) SMM (18.6 kg to 18.9 kg, *P* = 0.16). Dulaglutide group: Significant decrease in FM (21.9 kg to 18.9 kg, *P* = 0.037) and SMM (21.0 kg to 20.2 kg, *P* = 0.011)Exenatide BID Best et al. \[[@CR86]\]. Systematic review of 15 retrospective or prospective observational studies \[*N* ≥ 100\]. Duration 12 monthsTo assess the effectiveness of exenatide BID in clinical practiceSignificant reduction in body weight: − 2 to − 11 kg Klonoff et al. \[[@CR101]\]. Study of 3 open-ended, open-label, uncontrolled trials \[*N* = 217\]. Duration ≥ 3 yearsTo evaluate the effects of exenatide therapy on glycaemic control, body weight, cardiometabolic markers and safetyProgressive reduction in body weight (− 5.3 ± 0.4 kg; *P* \< 0.0001) Buse et al. \[[@CR102]\]. Interim analysis of pooled data from open-label, uncontrolled extension of 3 double-blind, placebo-controlled trials \[*N* = 974\]. Duration 2 yearsTo assess the metabolic effects of exenatide treatment on diabetes, obesity and hepatic biomarkersProgressive reduction in body weight (mean reduction − 4.7 ± 0.3 kg; *P* \< 0.001) Iglesias et al. \[[@CR103]\]. Uncontrolled, prospective study. Duration 3--6 monthsTo evaluate weight and metabolic effects of exenatide in patients with T2DM and obese patients waiting for BSSignificant reduction in body weight (− 12.5 kg) and waist circumference (-- 13 cm); *P* \< 0.0001. BMI reduction to \< 35 kg/m^2^ in about 20% of patients Viswanathan et al. \[[@CR104]\]. Retrospective study \[*N* = 52\]. Duration 4 months with follow-up period of 26 weeksTo evaluate the effect of exenatide BID on clinical parameters in obese patients with T2DM in whom hyperglycaemia was inadequately controlledAt 26 weeks follow-up, patients on regular exenatide dosing had body weight reduction (6.46 ± 0.8 kg; *P* \< 0.001)Exenatide QW Grimm et al. \[[@CR88]\]. Post hoc analysis of integrated data from DURATION trials (6 randomised, comparator-controlled) \[*N* = 1379\]. Duration 24--30 weeksTo evaluate the efficacy, safety and tolerability of EQW in patients with T2DMProgressive reductions in body weight (LSM − 2.5 kg; 95% CI − 2.8 to − 2.3 kg). At endpoint, weight loss was evident in 76% of the population Jabbour et al. \[[@CR105]\]. Post hoc analysis, DURATION-8 study \[*N* = 574\]. Duration 28 weeksTo assess the effects of EQW plus dapagliflozin versus EQW, or dapagliflozin on body weight in patients with T2DM with inadequately controlled with metformin monotherapyReduction in weight: EQW plus dapagliflozin group: (− 3.55 ± 0.29 kg); Significant vs. EQW group (− 1.56 ± 0.29 kg; *P* \< 0.001) vs. dapagliflozin (− 2.22 ± 0.28 kg; *P* \< 0.001).Liraglutide Blonde and Russell-Jones \[[@CR106]\]. Overview of LEAD (1--5) trials \[*N* \> 4000\]. Duration 26--52 weeksTo evaluate the safety and efficacy of liraglutide with or without OAD drug therapy in patients with T2DMLiraglutide vs. comparators: Significantly greater weight reduction (1--3.24 kg). Greater weight loss in subjects with high BMIs Davies et al. \[[@CR107]\]. Randomised, double-blind, placebo-controlled, parallel-group trial. SCALE Diabetes RCT \[*N* = 846\]. Duration 56 weeksTo evaluate the efficacy and safety of liraglutide versus placebo for weight management in overweight or obese adults with T2DMWeight loss: 6.0% (6.4 kg) (liraglutide 3.0 mg), 4.7% (5.0 kg) (liraglutide 1.8 mg), 2.0% (2.2 kg) (placebo). Weight loss of ≥ 5% and \> 10%: 54.3% and 25.2% (liraglutide 3.0 mg), 40.4% and 15.9% (liraglutide 1.8 mg), 21.4% and 6.7% (placebo) Gorgojo-Martinez et al. \[[@CR108]\]. Retrospective study of 2 cohorts \[*N* = 164, *n* = 15 with previous BS and *n* = 149 without BS\]. Duration 2 yearsTo evaluate the effectiveness and tolerability of liraglutide for 2 years in patients with and without previous BS and T2DM with obesitySignificant weight reduction: BS group: Δ weight − 3.4 kg;Non-BS group: Δ weight − 3.8 kg; (*P* \< 0.05)Lixisenatide Anderson et al. \[[@CR91]\] Pooled analysis of 11 phase 3 RCTs of the GetGoal programmeTo evaluate the efficacy and safety profiles of lixisenatide in patients with T2DMEffectively reduced body weight across a variety of patient types (reduction of − 0.2 to − 2.96 kg)Semaglutide Ahren et al. \[[@CR109]\]. Post hoc analysis of SUSTAIN (1--5) trials \[*N* = 3899\]. Duration 30 or 56 weeksTo evaluate the consistency of semaglutide-induced weight loss across baseline BMI subgroupsBody weight decreased by 2.5--5.7 kg (0.5 mg) and 2.0--7.9 kg (1.0 mg), versus 3.7 kg with comparators. Significantly greater proportions of subjects achieved weight loss (≥ 5% and ≥ 10%) with semaglutide versus comparators across all BMI subgroups (*P* \< 0.05)GLP-1 RAs: Exenatide BID, albiglutide, dulaglutide, liraglutide and lixisenatide Vilsboll et al. \[[@CR110]\]. Meta-analysis including 21 trials \[*N* = 6411 participants; GLP-1 RAs, *n* = 3395 and control groups, *n* = 3016\]. Duration 20 weeksTo assess the effect of GLP-1 RAs versus placebo, no intervention or other antidiabetic interventions for weight loss in overweight patients with or without T2DMGLP-1 RAs vs. control groups: Greater reduction in weight(WMD − 2.9 kg, 95% CI − 3.6 to − 2.2) Madsbad \[[@CR96]\]. Review including 9 phase 3 head-to-head trials and 1 large phase 2 study \[*N* = 812\]. Duration ∼ 6 monthsTo evaluate the relative clinical benefits of GLP-1 RAsWeight reduction with liraglutide was similar to exenatide BID but greater than that observed with EQW, albiglutide and dulaglutide Trujillo et al. \[[@CR111]\]. Review of 8 head-to-head trials from phase 3 clinical trial programs. Duration 24--32 weeksTo evaluate the safety and efficacy of GLP-1 RA active comparatorsDulaglutide and exenatide BID: Similar weight loss. Liraglutide vs. dulaglutide: Greater weight loss with liraglutide Robinson et al. \[[@CR112]\]. Systematic review and meta-analysis of 32 RCTs. Duration 16 weeks--4.5 years with follow-up of 12 weeksTo analyse the effects of GLP-1 RAs exenatide (BID and QW) and liraglutide on body weightAt 12 weeks' follow-up, body weight decreased as follows: − 3.31 kg for GLP-1 RAs vs. active control (95% CI − 4.05 to − 2.57); − 1.22 kg for GLP-1 RAs vs. placebo (95% CI − 1.51 to − 0.93)Comparative efficacy of bariatric surgery, incretin-based therapy (glucagon-like peptide-1 analogues) and SGLT2 inhibitors Bhandari et al. \[[@CR113]\]. Prospective study \[*N* = 90\]. Duration 12 monthsTo assess the comparative efficacy of bariatric surgery, GLP-1 analogues and SGLT2 inhibitors in class 1 obese Indian patients with T2DM for a median duration of 3 yearsClinically important weight loss (loss of \> 5% of usual body weight over 6 to 12 months) and a significant reduction in HbA1c occurred in patients treated with bariatric surgery and GLP-1 RAs; however, not in the case of patients treated with SGLT2iGLP-1 RAs: clinical impact on waist circumferenceExenatide BID Iglesias et al. \[[@CR103]\]. Uncontrolled, prospective study \[*N* = 100\]. Duration 6 monthsTo evaluate weight and metabolic effects of exenatide (after 3 and 6 months) in patients with T2DM and obese patients waiting for BSSignificantly reduced body weight (− 12.5 kg) and waist circumference (--13 cm); *P* \< 0.0001. BMI was reduced to \< 35 kg/m^2^ in about 20% of patients Sun et al. \[[@CR114]\]. Systematic review and network meta-analysis of 17 RCTs \[*N* = 4365\]. Duration ≥ 8 weeksTo assess the effect of GLP-1 RAs on waist circumference for T2DM patientsSignificant waist circumference reduction vs. placebo: − 5.24 cm (liraglutide 1.8 mg QD) (95% CI − 7.68, − 2.93), − 4.73 cm (liraglutide 1.2 mg QD) (95% CI − 6.68, − 2.65), − 1.34 cm (exenatide 10 μg BID) (95% CI − 2.00, − 0.75). Significantly decreased waist circumference by − 1.73 cm (liraglutide 1.8 mg vs. sitagliptin) (95% CI − 3.04, − 0.55). Decreased waist circumference: 98.36% (liraglutide 1.8 mg), 91.82% (liraglutide 1.2 mg)*AWARD* assessment of weekly administration of LY2189265 in diabetes (dulaglutide, 0.75 mg or 1.5 mg QW), *BS* bariatric surgery, *BMI* body mass index, *DURATION* diabetes therapy utilization: researching changes in A1C, weight and other factors through intervention with exenatide QW (extended-release exenatide, 2 mg, once weekly), *EQW* exenatide QW, *FM* fat mass, *GETGOAL* GLP-1 agonist AVE0010 in patients with type 2 diabetes mellitus for glycaemic control and safety evaluation (lixisenatide, 20 µg once daily), *GLP-1 RA* glucagon-like peptide-1 receptor agonist, *HbA1c* glycated haemoglobin, *HD* haemodialysis, *LEAD* liraglutide effect and action in diabetes (liraglutide 1.2 mg or 1.8 mg daily), *OAD* oral antidiabetics, *RCT* randomised controlled trial, *SCALE* satiety and clinical adiposity---liraglutide evidence in individuals with and without diabetes, *SGLT2* sodium-glucose co-transporter-2, *SMM* skeletal muscle mass, *SUSTAIN-6* trial to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes (semaglutide, 0.5 mg or 1.0 mg QW), *T2DM* type 2 diabetes mellitus, *WMD* weighted mean difference

Cardiovascular Health {#Sec23}
---------------------

GLP-1 RAs have been reported to be beneficial for cardiovascular health in patients with T2DM as these drugs aid in controlling cardiovascular (CV) risk factors such as hyperglycaemia, dyslipidaemia, weight gain and arterial hypertension (Tables [14](#Tab14){ref-type="table"}, [15](#Tab15){ref-type="table"}). Evidence also suggests that these drugs may have beneficial effects on endothelial function, coronary ischaemia and heart failure \[[@CR117]\]. Several cardiovascular outcome trials (CVOTs) have been conducted or are being conducted to elucidate CV safety of GLP-1 RAs in patients. The key results from CVOTs for various GLP-1 RAs are presented in Table [16](#Tab16){ref-type="table"}. In addition, key systematic reviews and meta-analyses involving CVOTs and other studies discussing CV outcomes with the use of GLP-1 RA are presented in Table [17](#Tab17){ref-type="table"}.Table 14GLP-1 RAs: clinical impact and benefits on lipid profileStudy detailsAimHighlightsExenatide QW Grimm et al. \[[@CR88]\]. Post hoc analysis of integrated data from 6 randomised, comparator-controlled trials of EQW (DURATION trials) \[*N* = 1379\]. Duration 24--30 weekTo evaluate the efficacy, safety and tolerability of EQW in patients with T2DMSignificant reductions in fasting lipid levels (in mg/dL): total cholesterol, − 6.5 \[95% CI − 8.2 to − 4.7\]; LDL-C, − 3.9 \[95% CI − 5.3 to − 2.5\]; triglycerides, − 6% \[95% CI − 8 to − 4\] Trautmann et al. \[[@CR115]\]. Post hoc analysis of pooled data from 3 studies (DURATION 1--3 extension studies) \[*N* = 329\]. Duration 3 yearsTo evaluate efficacy and safety of EQW versus insulin glargine in patients with T2DMAt week 156, final LDL-C reductions (in mmol/L) − 0.13 ± 0.73 (range − 0.01 to − 0.15 mmol/L). Week 52 onwards, final HDL-C increase of 0.08 ± 0.20 mmol/L (*P* \< 0.05). Final reductions in total cholesterol were as follows: − 0.11 ± 0.93 mmol/L (EQW), − 0.15 ± 0.86 mmol/L (insulin glargine). Final reductions in triglycerides were as follows: − 0.05 ± 1.79 mmol/L (EQW), − 0.14 ± 1.19 mmol/L (insulin glargine) Sheu et al. \[[@CR75]\]. Post hoc analysis of pooled data \[*N* = 4625\]. Duration 24--30 weeksTo evaluate the efficacy and safety of exenatide twice daily and EQW in Asian versus white patients with T2DMChange across lipid outcomes were similar in Asian and white populations. Final reductions in triglycerides were as follows: − 0.12 mmol/L (Asian) (95% CI − 0.21 to 0.02; *P* = 0.0206 vs. baseline), -- 0.18 mmol/L (White) (95% CI − 0.27 to − 0.08; *P* = 0.0004 vs. baseline)LiraglutideMultiple GLP-1 analogues Sun et al. \[[@CR116]\]. Systematic review and network meta-analyses of 35 RCTs \[*N* = 14,340\]. Duration ≥ 8 weeksTo assess the effect of GLP-1 RAs on lipid profiles in patients with T2DMGLP-1RAs decreased HDL-C versus thiazolidinediones with a range of − 0.06 mmol/L \[95% CI − 0.11 to − 0.01\] to − 0.13 mmol/L \[95% CI − 0.17 to − 0.10\] respectively. Significant LDL-C reduction for all GLP-1 RAs vs. placebo (− 0.08 to − 0.16 mmol/L), insulin (− 0.10 to − 0.19 mmol/L) and TZD (− 0.16 to − 0.24 mmol/L). Significant triglyceride level reduction with liraglutide 1.8 mg once daily as compared to placebo: − 0.30 mmol/L \[95% CI − 0.49 to − 0.11\]*DURATION* diabetes therapy utilization: researching changes in A1C, weight and other factors through intervention with exenatide QW (extended-release exenatide, 2 mg, once weekly), *EQW* exenatide QW, *HDL-C* high density lipoprotein cholesterol, *GLP-1 RA* glucagon-like peptide-1 receptor agonist, *LDL-C* low density lipoprotein cholesterol, *RCTs* randomised controlled trials, *T2DM* type 2 diabetes mellitus, *TZD* thiazolidinedionesTable 15GLP-1 RAs: clinical impact and benefits on BPReference/studyStudy designDurationChange in SBP (mmHg)Change in DBP (mmHg)Dulaglutide Giorgino et al. \[[@CR118]\]. AWARD-2Randomised open-label comparator (double blind to dulaglutide dose), parallel-arm study78 weeks− 0.70 ± 0.85 (1.5 mg), − 0.59 ± 0.85 (0.75 mg) (on treatment with dulaglutide)− 0.44 ± 0.52 (1.5 mg), − 0.36 ± 0.52 (0.75 mg) (on treatment with dulaglutide) Umpierrez et al. \[[@CR119]\]. AWARD-3Randomised, parallel-arm, double-blind, double-dummy, non-inferiority study52 weeks− 0.1 ± 0.88 (1.5 mg),  − 2.7 ± 0.88 (0.75 mg)− 0.3 ± 0.60 (1.5 mg), − 1.4 ± 0.59 (0.75 mg) Skrivanek et al. \[[@CR120]\]. AWARD-5Randomised, multicentre, double-blind, parallel-arm study26 weeksNA− 0.02 (0.25 mg), − 0.26 (0.5 mg), − 0.65 (0.75 mg), − 0.92 (1.0 mg), − 0.99 (1.5 mg), − 0.78 (2.0 mg), − 0.57 (3.0 mg) Dungan et al. \[[@CR71]\]. AWARD-6Phase 3, randomised, open-label, parallel-group study26 weeks− 3.36 ± 0.7 (1.5 mg)− 0.22 ± 0.4 (1.5 mg) Ferdinand et al. \[[@CR121]\]Randomised, double-blind, placebo-controlled study26 weeks− 2.5 ± 0.6 (1.5 mg), − 1.6 ± 0.6 (0.75 mg)0.3 ± 0.4 (1.5 mg), − 0.1 ± 0.4 (0.75 mg)Exenatide (2 mg/week or 5--10 µg/day) and liraglutide (1.2 mg or 1.8 mg/day) Wang et al. \[[@CR122]\]Meta-analyses of 16 crossover or parallel design, randomised controlled and extended open-label RCTs\> 12 weeksExenatide 2 mg/week vs. placebo − 5.24 (95% CI − 6.88 to − 3.59, *P* \< 0.00001). Exenatide 2 mg/week vs. insulin glargine − 3.46 (95% CI − 3.63 to − 3.29, *P* \< 0.00001). Liraglutide 1.2 mg vs. placebo − 5.60 (95% CI − 5.84 to − 5.36, *P* \< 0.00001). Liraglutide 1.2 mg vs. glimepiride − 2.38 (95% CI − 4.75 to − 0.01, *P* = 0.05). Liraglutide 1.8 mg vs. placebo − 4.49 (95% CI − 4.73 to − 4.26, *P* \< 0.00001) Liraglutide 1.8 mg vs. glimepiride − 2.62 (95% CI − 2.91 to − 2.33, *P* \< 0.00001)Exenatide-treated vs. placebo −5.91 (95% CI − 7.53 to − 4.28, *P* \< 0.00001). Exenatide-treated vs. sitagliptin− 0.99 (95% CI − 1.12 to − 0.87, *P* \< 0.00001)Exenatide BID Baretic et al. \[[@CR123]\]Open-label, intention-to-treat, phase 3 study52 weeks− 4.65 (5 and 10 µg) (with EBID treatment)− 1.48 (5 and 10 µg) (with EBID treatment) Sheu et al. \[[@CR75]\]Retrospective post hoc analysis12--30 weeks− 1.4 (Asian), − 1.2 (White)− 3.3 (Asian), − 2.8 (White) Moretto et al. \[[@CR124]\]Randomised, double-blind, placebo-controlled24 weeks− 3.7 ± 1.2 (both 5 and 10 µg)--2.3 ± 0.7 (10 µg) Ji et al. \[[@CR76]\]Randomised, comparator-controlled, open-label study26 weeks− 5.38 ± 0.86 (10 µg EBID group)− 2.26 ± 0.55 (10 µg EBID group) Rosenstock et al. \[[@CR83]\]. GetGoal-XPhase 3, randomised, parallel-group, open-label, multicentre, multinational, non-inferiority study24 weeks− 2.5 (10 µg exenatide group)− 1.3 (10 µg exenatide group) Best et al. \[[@CR86]\]Systematic review including 15 retrospective or prospective observational studies12 monthsSignificant reductions: − 2 to − 11 (10 µg exenatide)Exenatide QW Grimm et al. \[[@CR88]\]. Integrated DURATION trialsRandomised, comparator-controlled 6 trials, post hoc analysis24--30 weeks− 2.8 \[− 3.5 to − 2.1\] (on treatment with EQW)− 0.8 \[− 1.2 to − 0.4\] (on treatment with EQW)Exenatide BID and QW Sheu et al. \[[@CR75]\]Randomised, controlled, retrospective post hoc analysis12--30 weeks (exenatide BID) 24--30 weeks (exenatide QW)Exenatide BID − 3.3 (Asian), − 2.8 (White) (all *P* \< 0.001 vs. baseline), EQW-treated − 4.3 (Asian), -- 3.0 (White) (both *P* \< 0.0001 vs. baseline)Exenatide BID -- 1.4 (Asian), -- 1.2 (White). EQW-treated patients -- 1.1 (Asian) (*P* = 0.0052 vs. baseline), -- 0.6 (White) (*P* = 0.0283 vs. baseline)Exenatide (BID and QW) and liraglutide Robinson et al. \[[@CR112]\]Randomised comparator-controlled trials, systematic review and meta-analyses12 weeks follow-upGLP-1 agonists vs. placebo − 1.79 (− 2.94 to − 0.64). GLP-1 agonists vs. active control − 2.39 (− 3.35 to − 1.42)GLP-1 agonists vs. placebo − 0.54 (− 1.15 to 0.07). GLP-1 agonists vs. active control − 0.50 (− 1.24 to 0.24)Exenatide BID and QW, dulaglutide (0.75--1.5 mg), liraglutide (1.2--1.8 mg) Sun et al. \[[@CR125]\]Systematic review and network meta-analyses including 60 trials with 14 treatments≥ 12 weeksGLP-1RAs vs. placebo -- 1.84 mmHg (95% CI − 3.48 to -- 0.20). GLP-1RAs vs. insulin and sulfonylureas − 4.60 (95% CI − 7.18 to -- 2.03)Exenatide BID (10 μg) vs. placebo -- 1.08 mmHg (95% CI − 1.78 to − 0.33)Liraglutide Bailey et al. \[[@CR126]\]. LIRA-SWITCHPhase 4, randomised study26 weeks− 4.05 (1.8 mg liraglutide)− 0.27 (1.8 mg liraglutide) Ghosal et al. \[[@CR72]\]Retrospective real-world observational case note13 weeks− 10.23 (1.2 mg/day liraglutide)NS Kesavadev et al. \[[@CR127]\]Real-world, prospective study24 weeksNS− 5.3 (when treated with liraglutide) Wangnoo et al. \[[@CR128]\]. LEAD-InProspective, observational study26 weeks− 10.7 (1.8 mg liraglutide)− 5.0 (1.8 mg liraglutide) Fonseca et al. \[[@CR129]\]Pooled analysis (6 phase 3 studies)26 weeks− 2.7 ± 0.8 (1.2 mg), − 2.9 ± 0.7 (1.8 mg)NA Ahmann et al. \[[@CR130]\]Randomised, placebo-controlled, double-blind, parallel-group26 weeks− 5.8 (liraglutide treated)NA Azar et al. \[[@CR131]\]. LIRA- RAMADANRandomised, open-label, active-controlled, parallel-group study33 weeks− 3.45 (liraglutide treated)NS Yang et al. \[[@CR132]\]Randomised, double-blind, double-dummy, 4-arm, active control, phase 3 study16 weeksReduction \> 3A slight decrease in mean DBPLixisenatide Pfeffer et al. \[[@CR133]\]. ELIXA trialMulticentre, randomised, double-blind, placebo-controlled trial25 months− 0.8 (95% CI − 1.3 to − 0.3) (*P* = 0.001) (with lixisenatide) Tonneijck et al. \[[@CR134]\]Secondary analysis of a phase 4, single-centre, randomised, open-label, comparator-controlled, parallel-group intervention trial4 weeksPost breakfast: Lixisenatide vs. insulin glulisine+ 5.2 ± 2.9 (*P* = 0.087)Post breakfast: Lixisenatide vs. insulin glulisine +5.4 ± 1.4 (*P* \< 0.001) Rosenstock et al. \[[@CR83]\]. GetGoal-XPhase 3, randomised, parallel-group, open-label, multicentre, multinational, non-inferiority study24 weeks-- 2.9 (20 µg)-- 1.8 (20 µg)Lixisenatide 20 µg and liraglutide 1.2 and 1.8 mg Meier et al. \[[@CR135]\]Multicentre, randomised, open-label, 3-arm trial8 weeksLiraglutide 1.8 mg, -- 2.5 ± 7.7. Liraglutide 1.2 mg, − 0.5 ± 7.1. Lixisenatide 20 µg, 0.4 ± 6.4Liraglutide 1.8 mg, 1.6 ± 4.7. Liraglutide 1.2 mg, 2.4 ± 4.7. Lixisenatide 20 µg, 0.8 ± 4.1Semaglutide QW Andreadis et al. \[[@CR136]\]. SUSTAIN-6 trialSystematic review and meta-analyses of 6 placebo-controlled and 7 active-controlled studies12--56 weeks (104 weeks for SUSTAIN-6)Semaglutide 0.5 mg vs. placebo -- 1.31 (95% CI 0.07--2.56,*I*^2^ = 0%), Semaglutide 1 mg vs. placebo WMD − 3.05 (95% CI − 4.63 to − 1.47,*I*^2^ = 21%), Semaglutide 0.5 mg vs. other antidiabetic agents − 1.78 (95% CI 0.43--3.13,*I*^2^ = 44%), Semaglutide 1 mg vs. other antidiabetic agents − 3.17 (95% CI 2.31--4.03,*I*^2^ = 0%)Semaglutide 1 mg vs. other antidiabetic agents -- 0.85 (95% CI − 1.54 to − 0.16,*I*^2^ = 30%) Ahren et al. \[[@CR137]\]. SUSTAIN-2Phase 3a, randomised, double-blind, double-dummy, active-controlled, parallel-group, multinational, multicentre study56 weeks− 5.1 (0.5 mg), − 5.6 (1 mg)− 2.0 (0.5 mg), −1.9 (1 mg) Pratley et al. \[[@CR138]\]. SUSTAIN-7Phase 3b randomised study40 weeks− 2.4 ± 0.76 (0.5 mg), − 4.9 ± 0.77 (1.0 mg)− 0.6 ± 0.48 (0.5 mg), − 2.0 ± 0.49 (1.0 mg)*BP* blood pressure, *DBP* diastolic blood pressure, *EBID* exenatide BID, *EQW* exenatide QW, *NA* not applicable, *NS* not significant, *SBP* systolic blood pressure, *RCTs* randomised controlled trials, *WMD* weighted mean difference^a^Only significant values (*P* \< 0.05) presentedTable 16Baseline characteristics and key results of CVOTs for GLP-1 RAsTrialEXSCELLEADERELIXASUSTAIN-6HARMONYDrug testedExenatide (QW) \[[@CR139], [@CR140]\]Liraglutide \[[@CR139], [@CR140]\]Lixisenatide \[[@CR139], [@CR140]\]Semaglutide \[[@CR139], [@CR140]\]Albiglutide \[[@CR141], [@CR142]\]Baseline characteristics DoseUp to 2 mg weeklyUp to 1.8 mg/dayUp to 20 μg/day0.5 or 1 mg weekly30--50 mg/week No. of patients14,7529340606832979463 Mean age (years)6164.359.964.664.1 Women (%)3836313931 Mean BMI (kg/m^2^)32.732.530.132.832.3 Mean HbA1c (%)8.18.77.78.78.7 Mean duration of diabetes (years)13.112.89.213.913.8 Prior CVD (%)7381.310083NA^a^ Heart failure (%)161722.52420.2 SBP (mmHg)136138130136134.7 eGFR \< 60 mL/min/1.73 m^2^ (%)21.3242228.510.6 ComparatorPlacebo and standard of carePlacebo and standard of carePlacebo and standard of carePlacebo and standard of carePlacebo and standard of care Median follow-up (years)3.23.82.12.11.5Results No. of primary events observed17441302844254338 Non-inferiority for MACE demonstrated?^b^YesYesYesYesYes Superiority for MACE^b^No differenceSuperior (13% reduction)No differenceSuperior (26% reduction)^c^Superior CV death reduced?NoYesNoNoNo All-cause mortality reduced?YesYesNoNoNo Difference in HbA1c (% units)0.270.41.00.530.63 Mean reduction in weight (kg)0.72.34.31.270.83Cited references to be visited for detailed information*BMI* body mass index, *CV* cardiovascular, *CVD* cardiovascular disease, *CVOT* cardiovascular outcome trials, *eGFR* estimated glomerular filtration rate, *ELIXA* evaluation of lixisenatide in acute coronary syndrome (lixisenatide, maximum dose 20 µg per day), *EXSCEL* exenatide study of cardiovascular event lowering trial (exenatide QW, 2 mg), *GLP-1 RA* glucagon-like peptide-1 receptor agonist, *HARMONY* trial to evaluate the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus, *HbA1c* glycated haemoglobin, *LEADER* liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (liraglutide, 1.8 mg QD), *MACE* major adverse cardiovascular events, *NA* not available, *SBP* systolic blood pressure, *SUSTAIN*-6 trial to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes (semaglutide, 0.5 mg or 1.0 mg QW)^a^Prior coronary artery disease, 70.5%; peripheral arterial disease, 25.0%; stroke, 17.7%; heart failure, 20.2%^b^Compared to placebo and standard of care^c^The comparison was not pre-specified and not to be used for regulatory purposesTable 17Key studies reporting cardiovascular outcomes with GLP-1 RA therapyStudy detailsAimHighlightsDulaglutide Ferdinand et al. \[[@CR143]\]. Meta-analysis of 9 randomised safety and efficacy trials \[*N* = 6010; dulaglutide, 3885; comparator therapy active or placebo, 2125\]To evaluate the CV risk in patients with T2DM treated with dulaglutidePatients who experienced primary 4-component MACE: 26 (0.67%) for dulaglutide vs. 25 (1.18%) for comparator (HR 0.57; adjusted 98.02% CI 0.30--1.10). No significant difference between the groups for 3-component MACE, 6-component MACE and all-cause mortality, (HR \< 1.0 for all). Dulaglutide does not increase major CV events risk in T2DM patientsExenatide BID Ratner et al. \[[@CR144]\]. Pooled analysis of retrospectively examined data from RCTs (8 blinded, 4 open label); \[Exenatide BID (*n* = 2316), pooled comparator (placebo, *n* = 971; or insulin, *n* = 658)\]To evaluate the CV safety of exenatide BID versus pooled comparator or insulin, in patients with T2DMExenatide use did not increase CV risk. Primary MACE RR 0.7, 95% CI 0.38--1.31 (calculated by the Mantel--Haenszel method as compared to pooled comparators)Multiple GLP-1 analogues: lixisenatide (up to a maximum dose of 20 μg QD), liraglutide (1.8 mg QD), semaglutide (0.5 mg or 1.0 mg QW) and extended-release exenatide (2 mg QW) Bethel et al. \[[@CR145]\]. Systematic review and meta-analysis of 4 CV outcome trials (EXSCEL, ELIXA, SUSTAIN-6, LEADER)To examine the overall CV safety and efficacy for multiple GLP-1 analogues in adult patients (\> 18 years) with T2DMGLP-1 RA treatment group vs. placebo: Significant 10% RRR in the 3-point major adverse CV event primary outcome (HR 0.90, 95% CI 0.82--0.99; *P* = 0.33), 13% RRR in CV mortality (HR 0.87, 95% CI 0.79--0.96; *P* = 0.007), 12% RRR in all-cause mortality (HR 0.88, 95% CI 0.81--0.95; *P* = 0.002), with low-to-moderate degree of heterogeneity between trials*CV* cardiovascular, *ELIXA* evaluation of lixisenatide in acute coronary syndrome (lixisenatide, maximum dose 20 µg per day), *EXSCEL* exenatide study of cardiovascular event lowering trial (exenatide QW, 2 mg), *LEADER* liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (liraglutide, 1.8 mg QD), *MACE* major adverse cardiac events, *HR* hazards ratio, *RRR* relative risk reduction, *RCTs* randomised controlled trials, *SUSTAIN*-*6* trial to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes (semaglutide, 0.5 mg or 1.0 mg qW), *T2DM* type 2 diabetes mellitus

CV protection has been demonstrated with liraglutide (The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results trial; LEADER), semaglutide (Semaglutide in Subjects with Type 2 Diabetes; SUSTAIN-6) and albiglutide (HARMONY). The effect was neutral with exenatide LAR (Exenatide Study of Cardiovascular Event Lowering Trial; EXSCEL) and lixisenatide (Evaluation of LIXisenatide in Acute coronary syndrome; ELIXA) \[[@CR146]\]. The result of Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial, which is reported to be the longest among the CVOT trials, is due to be published in the near future and may bring about new dimensions to CV health in patients with T2DM \[[@CR147], [@CR148]\].

Renal Health {#Sec24}
------------

GLP-1 RAs have both direct and indirect renoprotective effects. GLP-1 RAs directly exert their renoprotective effects by reducing the markers involved in renal hypoxia and those involved in the activation of the renin--angiotensin system. They also aid in preventing glomerular atherosclerosis. Indirect renoprotective effects include improved glucose control, BP and weight loss. Although available evidence supports reduction of albuminuria in patients treated with GLP-1 RAs, clear evidence for its effects on renal outcomes is still lacking. This is primarily because very few patients with advanced renal disease receive GLP-1 RA as a result of its poor tolerability in this patient subset \[[@CR149]\].

A more detailed discussion on the effects of each GLP-1 RA on renal health is presented with clinical evidence in Table [18](#Tab18){ref-type="table"}.Table 18GLP-1 RAs: clinical impact and benefits on renal healthStudy detailsAimHighlightsDulaglutide Tuttle et al. \[[@CR150]\]. Multicentre, open-label, randomised interventional study (AWARD-7) \[Dulaglutide 1.5 mg, *n* = 193 and 0.75 mg, *n* = 190 versus insulin glargine, *n* = 194\]. Duration 52 weeksTo investigate the efficacy and safety of dulaglutide (1.5 and 0.75 mg) vs. insulin glargine in T2DM patients and moderate-to-severe CKD (stage 3--4)At 52 weeks, higher eGFR was reported with dulaglutide 1.5 mg (LSM 34.0 mL/min/1.73 m^2^ \[SE 0.7\]; *P* = 0.005 vs. insulin glargine), dulaglutide 0.75 mg (LSM 33.8 mL/min/1.73 m^2^ \[0.7\]; *P* = 0.009 vs. insulin glargine) (for insulin glargine 31.3 mL/min/1.73 m^2^ \[0.7\]). UACR reduction with dulaglutide (1.5 mg and 0.75 mg) was not significantly different from insulin glargine. ESRD occurred in 38 participants: 4% (dulaglutide 1.5 mg), 7% (dulaglutide 0.75 mg), 8% (insulin glargine) Tuttle et al. \[[@CR151]\]. Pooled analysis of phase II and phase III studies of 9 clinical trials \[*N* = 6005\]. Duration 26 weeksTo evaluate the effects of dulaglutide on kidney function in patients with T2DMNo significant differences were observed for eGFR between dulaglutide group and comparators. Lower UACR values were observed for dulaglutide vs. placebo, active comparators and insulin glargine (at 26 weeks) and the values were dulaglutide vs. placebo 8.0 \[4.4--20.4\] vs. 8.0 \[4.4--23.9\] mg/g, *P* = 0.023; dulaglutide vs. active comparators 8.0 \[4.4--21.2\] vs. 8.9 \[4.4--27.4\] mg/g, *P* = 0.013; and dulaglutide vs. insulin glargine 8.9 \[4.4--29.2\] vs. 12.4 \[5.3--50.5\] mg/g, *P* = 0.029. Potential acute renal failure (in events/1000 patient-years): 3.4 (dulaglutide), 1.7 (active comparators), 7.0 (placebo). Dulaglutide treatment did not affect eGFR but demonstrated a slight decrease in albuminuriaExenatide BID Linnebjerg et al. \[[@CR152]\]. Open-label, observational study, 4 parallel study groups \[*N* = 31\]. Duration 30 weeksTo evaluate the PK, safety and tolerability of exenatide BID (5 or 10 µg) in patients with RIWell tolerated in mild and moderate RI groups. Therapeutic doses (5 and 10 mg) are unsuitable in severe RI or ESRDExenatide QW Loughlin et al. \[[@CR153]\]. Observational, real-world study; \[EQW (*n* = 2075), basal insulin (*n* = 73,610)\]. Duration 3 yearsTo evaluate the effectiveness and tolerability of EQW compared with basal insulin among injectable-drug-naïve patients with T2DM who are elderly or have RIIn elderly patients (age ≥ 65 years), HbA1c levels changed as follows: -- 0.50% (EQW), − 0.31% (BI initiators). Weight changed as follows: − 1.6 kg (EQW initiators), 0.2 kg (BI initiators). EQW initiators had a 1.45-fold increased risk of nausea and vomiting compared with BI initiators. In RI patients, HbA1c changed by − 0.58% (EQW), − 0.33% (BI initiators). Weight changed by − 1.9 kg (EQW initiators). No change (BI initiators). EQW initiators had a 1.28-fold increased risk of constipation and diarrhoea compared with BI initiators. The renal function, assessed according to eGFR, remained stable from baseline for both EQW and BI initiators, regardless of RILiraglutide Marso et al. \[[@CR154]\]; Leon et al. \[[@CR155]\]. LEADER \[*N* = 9340\]. Duration 3.8 yearsTo assess the long-term effects of liraglutide on cardiovascular outcomes and other clinically important eventsIn liraglutide-treated arm: 26% reduced macroalbuminuria(HR 0.74 \[0.60--0.91\]). 19% reduced urine ACR (CI 0.14%--0.24%). Gained significantly greater CV benefit who had an eGFR \< 60 mL/min/1.73 m^2^ (HR 0.69 \[0.57--0.85\]) than those with an eGFR \> 60 mL/min/1.73 m^2^ (HR 0.94 \[0.83--1.07\]). Doubling of serum creatinine concentration to an eGFR ≤ 45 mL/min/1.73 m^2^ was unaffected. ESRD or renal death incidence was small Davies et al. \[[@CR156]\]. Randomised, double-blind, placebo-controlled, parallel-group trial; LIRA-renal study \[liraglutide (*n* = 140) or placebo (*n* = 139)\]. Duration 26 weeksTo examine the efficacy and safety of liraglutide in patients with T2DM and moderate renal impairmentNo changes in renal function (eGFR relative ratio to baseline − 1% \[liraglutide\], + 1% \[placebo\]; estimated treatment ratio \[ETR\] 0.98, *P* = 0.36). The most common AEs were of GI in nature: 35.7% (liraglutide), 17.5% (placebo), with no difference in hypoglycaemic episodes Idorn et al. \[[@CR157]\]. Investigator-initiated, placebo-controlled, double-blind, parallel-group, randomised trial \[patients with T2DM and ESRD (*n* = 24) and control subjects with T2DM and normal kidney function (*n* = 23)\]. Duration 12 weeksTo evaluate the parameters related to the safety and efficacy of liraglutide in patients with T2DM and dialysis-dependent ESRDLiraglutide vs. control group: 49% increase in dose-corrected plasma trough concentration in ESRD group (95% CI 6--109, *P* = 0.02). Nausea and vomiting (initial and temporary) occurred more frequently in patients with ESRD (*P* \< 0.04). In both liraglutide-treated groups significant improvement in glycaemic control (*P* \< 0.01) and reduction in the dose of baseline insulin (*P* \< 0.04). Body weight reduction was observed in − 2.4 ± 0.8 kg, *P* = 0.22 (ESRD group) and 2.9 ± 1.0 kg, *P* = 0.03 (control group)Lixisenatide Pfeffer et al. \[[@CR133]\]. CVOT, ELIXA. Duration 25 monthsTo assess the effects of lixisenatide in patients with T2DM who had had a recent acute coronary eventMedian UACR increased to 24% (CI 19--30%) compared to placebo with an increase of 34% (CI 24--40%) Tonneijck et al. \[[@CR158]\]. Phase 4, single-centre, randomised, open-label, comparator-controlled, parallel-group intervention trial \[*N* = 35\]. Duration 8 weeksTo evaluate whether lixisenatide when added to insulin glargine ameliorates postprandial glomerular hyperfiltration in overweight patients with T2DM compared with insulin glulisineNo effect on eGFR (+0.1 mL/min/1.73 m^2^) \[95% CI − 9 to 9\] and ERPF (− 17 mL/min/1.73 m^2^ \[− 61 to 26\]), other (intra-)renal haemodynamics or renal damage markers as compared to insulin glulisine. Increased fractional sodium excretion \[+ 0.25% (0.09--0.41)\] and urinary pH \[+ 0.7 (0.3--1.2)\]. Unchanged: Plasma renin, angiotensin II and aldosterone levels. Decreased HbA1c level in both groups. PPBG was lower. Prolonged treatment resulted in sustained natriuretic effect in contrast to reports on long-acting GLP-1 RAs Hanefeld et al. \[[@CR159]\]. Post hoc assessment of 9 lixisenatide trials in the GetGoal clinical trial programme \[normal renal function (lixisenatide *n* = 2094, placebo *n* = 1150); renal impairment (mild: lixisenatide *n* = 637, placebo *n* = 414; moderate: lixisenatide*n* = 122, placebo *n* = 68)\]. Duration 12--24 weeksTo assess the efficacy and safety of once-daily lixisenatide in patients with T2DM with normal-to-moderate renal impairmentReduced HbA1c, PPBG and FBG in lixisenatide-treated patients vs. placebo. Mild renal impairment vs. normal kidney function: 14% higher incidence of GI, 10% higher incidence of nausea and vomiting (*P* = 0.003 for both)Semaglutide Marso et al. \[[@CR160]\]. CVOT, SUSTAIN-6 \[*N* = 3297\]. Duration 154 weeksTo assess the non-inferiority of semaglutide as compared with placebo in terms of cardiovascular safety in patients with T2DMTreatment reduced the frequency of new or worsening nephropathy (HR 0.64 \[0.46--0.88\], *P* = 0.005). Doubling of serum creatinine concentration to an eGFR ≤ 45 mL/min/1.73 m^2^, ESRD or renal death were unaffected; however, the event rate was too low (\< 1%) to sufficiently explore these outcomes Marbury et al. \[[@CR161]\]. Multicentre, single-dose, open-label, parallel-group study \[*N* = 54\]. Duration 21 daysTo compare the PK and tolerability of semaglutide (0.5 mg) in T2DM patients with mild/moderate RI or ESRD versus those with normal renal functionMean semaglutide exposure was 22% higher than subjects with normal renal function. No relationship between CL~CR~ and semaglutide exposure, or between CL~CR~ and semaglutide C~max~. Haemodialysis did not affect the PK of semaglutide*ACR* albumin-to-creatinine ratio, *AEs* adverse events, *AWARD* assessment of weekly administration of LY2189265 in diabetes (dulaglutide, 0.75 mg or 1.5 mg qw), *bi* basal insulin, *C*~max~ maximum plasma drug concentration, *CKD* chronic kidney disease, *CL*~*CR*~ creatinine clearance, *CVOT* cardiovascular outcome trials, *ELIXA* evaluation of lixisenatide in acute coronary syndrome (lixisenatide, maximum dose 20 µg per day), *eGFR* estimated glomerular filtration rate, *ERPF* effective renal plasma flow, *ESRD* end-stage renal disease, *EQW* exenatide QW, *FBG* fasting blood glucose, *GLP*-*1 RA* glucagon-like peptide-1 receptor agonist, *GI* gastrointestinal, *LSM* least squares mean, *PK* pharmacokinetics, *PPBG* postprandial blood glucose, *RI* renal impairment, *SE* standard error, *SUSTAIN*-*6* trial to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes (semaglutide, 0.5 mg or 1.0 mg QW), *T2DM* type 2 diabetes mellitus, *UACR*, urine albumin-to-creatinine ratio

Hepatic Health {#Sec25}
--------------

GLP-1 RAs may play a role in protecting both lean and fatty livers from ischaemic injury by inhibiting cell death and stimulating lipolysis \[[@CR162], [@CR163]\]. GLP-1 RAs can reduce hepatic steatosis and improve survival by enhancing the unfolded protein response by promoting macroautophagy. In addition, they improve insulin resistance and insulin sensitivity to prevent the progression of non-alcoholic fatty liver disease (NAFLD) \[[@CR164]--[@CR167]\]. The unique ability of GLP-1 RAs to promote weight loss, improve glycaemic control and potentially reverse hepatocyte injury, liver inflammation, and liver fibrosis makes them a novel and attractive therapeutic option for the treatment of non-alcoholic steatohepatitis (NASH) \[[@CR168]\]. A literature review evaluating the safety and efficacy of medications for the treatment of NASH in patients with T2DM reported favourable outcomes associated with the use of GLP-1 RAs with respect to reducing transaminases and steatosis along with improvements in insulin sensitivity and weight loss \[[@CR169]\]. Currently, there is limited clinical experience with GLP-1 RAs in patients with severe hepatic impairment \[[@CR170]\]. The beneficial effects of GLP-1 RAs on hepatic health are presented with clinical evidence in Table [19](#Tab19){ref-type="table"}.Table 19GLP-1 RAs: clinical impact and benefits on hepatic healthStudy detailsAimHighlightsDulaglutide Seko et al. \[[@CR171]\]. Retrospective study \[*N* = 15\]. Duration 12 weeksTo evaluate the efficacy and safety of dulaglutide (0.75 mg) in Japanese NAFLD patients with T2DMSignificant decrease in transaminase activities: AST -- 8.9 IU/L \[baseline = 50.4 ± 6\], *P* = 0.03; ALT − 11 IU/L \[baseline = 52.1 ± 7.2\], *P* = 0.003 was observed. Reduction in total body fat mass and liver stiffness was observedExenatide BID Klonoff et al. \[[@CR101]\]. Open-ended, open-label clinical trial \[*N* = 217 subjects; *n* = 116, baseline\]. Duration 3 yearsTo evaluate the effects of exenatide BID on glycaemic control, body weight, cardiometabolic markers and safetyALT reduction (− 10.4 ± 1.5 IU/L; *P* \< 0.0001) was observed; normal ALT levels were achieved in 41% of the treated patients Shao et al. \[[@CR172]\]. Prospective RCT \[*N* = 60\]. Duration 12 weeksTo evaluate the advantages of exenatide treatment on obesity and NAFLD with elevated liver enzymes in T2DM patientsExenatide vs. intensive insulin group: Significantly lower levels of ALT, AST and γGGT and correlated mean body weight change (*P* \< 0.001). Significantly (*P* \< 0.01) higher fatty liver reversal rate: 93.3% (exenatide), 66.7% (intensive insulin)Exenatide QW Bergenstal et al. \[[@CR173]\]. Analysis \[*N* = 675\]. Duration 52 weeksTo evaluate the potential effects of exenatide once weekly on glycaemic control and CV risk factorsSignificant ALT reduction: − 4.3 (0.71) IU/L, with greater improvements in patients with elevated ALT levels at baselineLiraglutide Armstrong et al. \[[@CR174]\]. A multicentre, double-blind, randomised, placebo-controlled phase II study; LEAN trial \[*N* = 23\]. Duration 48 weeksTo assess the administration of liraglutide (1.8 mg) versus placebo in patients who were overweight with clinically proven NASHResolution of definite NASH: 9 (39%) in liraglutide group, 2 (9%) in placebo (RR 4.3 \[95% CI 1.0--17.7\]; *P* = 0.019). Fibrosis progression: 2 (9%) of 23 patients in liraglutide group, 8 (36%) of 22 patients in the placebo group (RR 0.2 \[95% CI 0.1--1.0\]; *P* = 0.04). Liraglutide administration led to histological resolution of non-alcoholic steatohepatitisLixisenatide Gluud et al. \[[@CR175]\]. Systematic review and meta-analysis of 15 RCTs. Duration 4--76 weeksTo evaluate the effects of lixisenatide on elevated liver transaminase levels in patients with T2DMAt 29 weeks, beneficial effect on normalisation of ALT among obese patients (*P* = 0.01) or overweight (*P* = 0.004), but not among normal weight patients (*P* = 0.98) was observedMultiple GLP-1 RAs Carbone et al. \[[@CR176]\]. Systematic review and meta-analysis (random-effects model) of 4 studies \[*N* = 136\]. Duration 16--56 weeksTo evaluate the efficacy of incretin-based therapies (GLP-1 RA and DPP4i) in treating NAFLD via a structured retrieval and pooled analysis of relevant studiesPost incretin-based therapies: Significant ALT reduction (MR 14.1 IU/L; 95% CI 8.3--19.8, *P* \< 0.0001). Significant reduction (*P* \< 0.05) in steatosis, inflammation and fibrosis in imaging and tissue data was demonstrated in 2 studies Cuthbertson et al. \[[@CR177]\]. Prospective study \[*N* = 25\]. Duration 6 monthsTo determine the impact of GLP-1 RA therapy on IHL levels in obese T2DM patients with hepatic steatosis, and evaluate the inter-relationship between changes in IHL with those in HbA1c, body weight, and volume of abdominal VAT and SATTreatment group associated with mean weight loss of 5.0 kg (95% CI 3.5--6.5), mean HbA1c reduction of 1.6% (95% CI 0.8--2.4), 42% relative reduction in IHL (95% CI 16.5--59.3). In individuals with highest pre-treatment levels, a greater IHL reduction was observed*ALT* alanine aminotransferase, *AST* aspartate aminotransferase, *CV* cardiovascular, *DPP*-4i dipeptidyl peptidase-4 inhibitor, *GLP*-*1 RA* glucagon-like peptide-1 receptor agonist, *GGT* gamma-glutamyl transferase, *HbA1c* glycated haemoglobin, *IHL* intrahepatic lipid, *LEAN* liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis, *NAFLD* non-alcoholic fatty liver disease, *NASH* non-alcoholic steatohepatitis, *RCT* randomised controlled trial, *RR* relative risk, *SAT* subcutaneous adipose tissue, *T2DM* type 2 diabetes mellitus, *VAT* visceral adipose tissue

### Pancreatitis {#Sec26}

GLP-1 RAs are recommended to be used with caution/not used in patients with a familial/personal history of pancreatitis depending on the respective prescribing information \[[@CR178]\]. A few clinical studies and meta-analyses focussing on pancreatitis are presented in Table [20](#Tab20){ref-type="table"}.Table 20GLP-1 RAs: clinical impact and benefits in pancreatitisStudy detailsAimHighlightsStorgaard et al. \[[@CR179]\]. Systematic review and meta-analysis of 3 multicentre, double-blinded, placebo-controlled RCTs (ELIXA, LEADER, SUSTAIN-6) \[GLP-1 RA treated, *n* = 9347; placebo treated, *n* = 9353\]. Duration 24 monthsTo assess the risk of AP (predefined AE) in patients with T2DM with GLP-1 RAGLP-1 RA was not associated with increased risk of AP (OR 0.745 \[95% CI 0.47--1.17\]).Dulaglutide Nauck et al. \[[@CR180]\]. Integrated assessment of 9 trials, 4 phase 2 trials (trials 1--4) and 5 phase 3 confirmatory trials (AWARD 1--5) \[dulaglutide (*n* = 4006), placebo (*n* = 703), insulin glargine (*n* = 1541)\]. Duration 104 weeksTo evaluate the risk of AP during treatment with dulaglutide, placebo and active comparators^a^AP was confirmed in 7 patients distributed in all groups. Exposure-adjusted incidence rates (in patients/1000 patient-years) were as follows: dulaglutide group 0.85, placebo group 3.52 and sitagliptin group 4.71Liraglutide Jensen et al. \[[@CR181]\]. Post hoc review of pooled and patient-level data of phase 2 and 3 RCTs \[*N* = 9016\]. Duration 1 yearTo report the incidence of AP and CP in T2DM trials of liraglutide vs. active comparator groups^b^ vs. placeboAP cases: 8 (liraglutide) and 1 (comparator group, glimepiride). AP and CP incidence reports were greater with liraglutide than comparators Steinberg et al. \[[@CR182]\]. Secondary analyses of pooled data of the phase 3a, 4 randomised, placebo-controlled trials from the SCALE clinical development programme \[*N* = 5358\]. Duration 32 weeks--3 yearsTo investigate the association between amylase/lipase activity levels and subsequent AP occurrenceLiraglutide resulted in dose-independent, reversible increase in amylase/lipase activity. Gallstones possibly contributed to 50% of AP cases*AE* adverse event, *AP* acute pancreatitis, *AWARD* assessment of weekly administration of LY2189265 in diabetes (dulaglutide, 0.75 mg or 1.5 mg QW), *CP* chronic pancreatitis, *ELIXA* evaluation of lixisenatide in acute coronary syndrome (lixisenatide, maximum dose 20 µg per day), *GLP*-*1 RA* glucagon-like peptide-1 receptor agonist, *LEADER* liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (liraglutide, 1.8 mg QD), *OR* odds ratio, *RCTs* randomised controlled trial, *SCALE* satiety and clinical adiposity---liraglutide evidence in individuals with and without diabetes, *SUSTAIN*-*6* trial to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes (semaglutide, 0.5 mg or 1.0 mg QW), *T2DM* type 2 diabetes mellitus^a^Including metformin, sitagliptin, exenatide BID and insulin glargine^b^Glimepiride, rosiglitazone, insulin glargine, sitagliptin and exenatide

### Cholelithiasis {#Sec27}

GLP-1 RAs are known to pose a significantly increased risk of cholelithiasis \[[@CR183]\]. The key clinical evidence on cholelithiasis associated with GLP-1 RAs is presented in Table [21](#Tab21){ref-type="table"}.Table 21GLP-1 RAs: clinical impact and benefits in cholelithiasisGLP-1 RAs included in the studyStudy detailsAimHighlightsExenatide, liraglutide, lixisenatide, albiglutide, dulaglutide and semaglutide \[[@CR183]\]Systematic review and meta-analysis of randomised controlled trials \[GLP-1 RA (*n* = 33,167), comparator arms (*n* = 26,683)\]. Duration 41.7 weeksTo evaluate the effect of GLP-1 RA treatment on the incidence of pancreatitis, pancreatic cancer and cholelithiasis in patients with T2DMSignificant increase in cholelithiasis with GLP-1 RAs (OR 1.30 \[95% CI 1.01--1.68\], *P* = 0.041). No significant difference in incidence of pancreatitis and pancreatic cancer in both the arms*GLP*-*1 RA* glucagon-like peptide-1 receptor agonist, *OR* odds ratio, *T2DM* type 2 diabetes mellitusTable 22Data on GLP-1 RA use in patients with CKD (based on European Union label)Drug class and dosingeGFR (mL/min/1.73 m^2^) (associated stage)GLP-1 RAsLicensed dose60--89 (stage 2)45--59 (stage 3a)30--44 (stage 3b)15--29 (stage 4)\< 15 (stage 5)Dulaglutide QW \[[@CR186]\]0.75--1.5 mg SC injection QW✔✔✔✗✗Exenatide BID \[[@CR187]\]5--10 µg SC injection BID✔✔^a^--✗✗Exenatide QW \[[@CR188]\]2 mg SC injection QW✔✔^a^✗✗✗Liraglutide QD \[[@CR189]\]0.6--1.8 mg SC injection QD✔✔✔✗✗Lixisenatide QD \[[@CR190]\]10--20 µg SC injection QD✔✔^a,b^--✗✗Semaglutide QW \[[@CR191]\]0.25, 0.5 and 1 mg, SC injection QW✔✔^a^✔^a^✔^a^✗*CKD* chronic kidney disease, *eGFR* estimated glomerular filtration rate, *GLP*-1 *RA* glucagon-like peptide-1 receptor agonist, *SC* subcutaneous, ✔ indicated and no dose adjustment required, -- indication may be variable/consider dose reduction, frequent monitoring and relevant health status, ✗ contraindicated^a^No dose adjustment required if eGFR is \> 50 mL/min^b^Contraindicated if eGFR \< 50 mL/minTable 23GLP-1 RAs in a special population: the elderlyStudy detailsAimHighlightsDulaglutide (1.5 and 0.75 mg) Boustani et al. \[[@CR195]\]. Pooled analysis from 6 phase 3 clinical studies \[≥ 65 years, *n* = 958; \< 65 years, *n* = 4213\]. Duration 26 weeksTo evaluate the efficacy and safety of dulaglutide in elderly patients with T2DMLower hypoglycaemia incidence if patients were not on concomitant SU or insulin therapy. Similar GI AEs incidence with both dosesExenatide BID (10 μg) Pencek et al. \[[@CR196]\]. Post hoc analysis from 16 RCTs (≥ 65 years, *n* = 454; \< 65 years, *n* = 1613). Duration 12--30 weeksTo assess the efficacy and safety of exenatide BID in patients with T2DMImprovements in HbA1c, FBG and lipid levels (except HDL-C) in both age groups. ≥ 65 years age group: Lower hypoglycaemia incidence (1.2%) if not on concomitant SU and fewer fall-related injuriesExenatide QW (2 mg) Loughlin et al. \[[@CR153]\]. Observational, real-world study \[EQW (*n* = 2075), BI (*n* = 73,610)\]. Duration 3 yearsTo evaluate the effectiveness and tolerability of EQW compared with BI among injectable-drug-naïve patients with T2DM who are elderly (age ≥ 65 years) or have RIIn elderly patients, HbA1c levels changed by -- 0.50% (EQW initiators), and − 0.31% (BI initiators) from baseline to follow-up. Weight changed by − 1.6 kg (EQW initiators) and 0.2 kg (BI initiators). Stable renal function from baseline for both initiator groups. 1.45-fold increased risk of nausea and vomiting with EQW initiators than BI initiators Pencek et al. \[[@CR197]\]. Post hoc analysis of pooled data from 7 randomised, controlled, phase 3 trials \[*n* = 1719) including age (\< 65 or ≥ 65 years). Duration 24--30 weeksTo evaluate the efficacy and tolerability of EQW in patients with T2DMSignificant improvements in HbA1c, FBG and body weight, BP, lipids. Most common AEs: GI in natureLiraglutide (up to 1.8 mg/day) Gilbert et al. \[[@CR198]\]. Post hoc analysis of randomised, placebo-controlled, double-blind, CV outcomes LEADER trial \[*N* = 9340\]. Duration 3.5--5 yearsTo assess the risk of CV events and all-cause mortality in elderly patients with T2DMSignificant reduction in CV risk events and all-cause mortality (*P* \< 0.05) as compared to placebo Chitnis et al. \[[@CR199]\]. Real-world retrospective cohort study \[≥ 65 years (*n* = 517)\]. Duration 6--12 monthsTo assess the clinical effectiveness of liraglutide in patients with T2DMSignificant and sustained reduction in HbA1c and weight (*P* \< 0.01). No evidence of severe hypoglycaemiaLixisenatide (20 µg) Raccah et al. \[[@CR200]\]. Pooled data from 6 placebo-controlled phase 3 trials from lixisenatide \[elderly (≥ 65 years, *n* = 544) and very elderly (≥ 75 years, *n* = 79)\]. Duration 12--24 monthsTo evaluate the efficacy and safety of lixisenatide QD in elderly and very elderly patientsPlacebo-adjusted HbA1c reductions were comparable with the younger age groups (\< 65 and \< 75 years old). Maintained efficacy in patients with more severe β-cell dysfunction. Reported symptomatic hypoglycaemia in patients with insulin as concomitant medicationSemaglutide (0.5 or 1.0 mg) Warren et al. \[[@CR201]\]. Pooled analysis of phase 3 SUSTAIN 1--5 trials (elderly ≥ 65 years,*n* = 854; non-elderly \< 65 years, *n* = 3045). Duration 30--56 weeksTo assess the efficacy and safety of semaglutide vs. comparators in patients with T2DMConsistent improvement in HbA1c and body weight across both age groups. \> 85% of treated elderly patients achieved a less stringent target of HbA1c \< 8%. Premature treatment discontinuations were higher in elderly versus non-elderly patients. No increased risk of hypoglycaemia was observed*AEs* adverse events, *BI* basal insulin, *EQW* exenatide QW, *CV* cardiovascular, *FBG* fasting blood glucose, *GI* gastrointestinal, *GLP*-*1 RA* glucagon-like peptide-1 receptor agonist, *HbA1c* glycated haemoglobin, *HDL*-*C* high-density lipoprotein cholesterol, *LEADER* liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (liraglutide, 1.8 mg QD), *RCTs* randomised controlled trial, *RI* renal impairment, *SU* sulfonylurea, *SUSTAIN*-6 trial to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes (semaglutide, 0.5 mg or 1.0 mg QW), *T2DM* type 2 diabetes mellitus

GLP-1 RAs Use in Complicated Diabetes and Special Populations {#Sec28}
=============================================================

GLP-1 RA use in patients with cardiovascular complications, renal impairment and hepatic impairment along with their use in elderly, pregnant and lactating women is discussed here along with relevant clinical evidence. Special situations including fasting have been discussed.

GLP-1 RAs Use in Complicated Diabetes {#Sec29}
-------------------------------------

### Patients with Cardiovascular Complications {#Sec30}

Patients with T2DM are at a higher risk of developing CVD, which in turn is recognised to be the leading cause of death in patients with diabetes \[[@CR184]\]. Although the use of these agents is encouraged in patients with asymptomatic and stable CAD, there is no clear evidence regarding their usage in acute myocardial infarction. Hence, factors to be considered before/during the use of GLP-1 analogues in such cases could be a pragmatic approach based on prescribing information, available clinical evidence and clinical sense of physicians \[[@CR185]\]. The CV safety of GLP-1 RAs was presented in previous sections.

### Patients with Renal Impairment {#Sec31}

Exenatide and lixisenatide are predominantly cleared by the kidney. Exenatide dosage is not recommended to be increased in patients with an eGFR of 30--60 mL/min/1.73 m^2^. Both exenatide and lixisenatide are contraindicated in patients with eGFR \< 30 mL/min/1.73 m^2^. Although clearance of liraglutide and dulaglutide is predominantly hepatic, administration of these drugs in patients with renal impairment needs to be considered with caution. This is largely because of the GI side effects and risk of associated volume depletion in case of chronic kidney disease (CKD) and brittle renal haemodynamics \[[@CR149]\]. The renal safety of GLP-1 RAs has been discussed in previous sections.

Recommendations for the usage of GLP-1 RA in T2DM patients with renal impairment (as per the European label) are presented in Table [22](#Tab22){ref-type="table"}.

### Patients with Hepatic Impairment {#Sec32}

Elimination of GLP-1 RAs does not occur mainly by hepatic metabolism. As discussed in the previous sections, exenatide is primarily eliminated by the kidneys, whereas liraglutide and dulaglutide are metabolised endogenously into their component amino acids by general protein catabolism pathways. No specific organ is presumed to be the major route of elimination for GLP-1 RAs. It is important to note that there is limited information available on the safety and efficacy of GLP-1 RAs in patients with hepatic impairment. Prescribing information of the respective products advises cautious use in this patient population; however, there is no dosage adjustment recommended \[[@CR192], [@CR193]\]. The impact of GLP-1 RAs on hepatic health is presented in the clinical impact section.

GLP-1 RAs Use in Special Situations {#Sec33}
-----------------------------------

### Elderly {#Sec34}

Characteristics that inform the choice of effective antidiabetic medications in the elderly include medications with relatively low risk of hypoglycaemia and glycaemic variability without overt GI side effects to prevent malnutrition and worsening frailty. It is important to reduce regimen complexity and avoid episodes of hypo- and hyperglycaemia. This should be specifically considered in patients with cognitive problems. Ageing is described as a progressive impairment in carbohydrate tolerance which may be related to disorderly insulin release, reduced insulin production, reduced GLP-1 secretion, increased adiposity, sarcopenia and physical inactivity. GLP-1 RAs are known to have low risk of hypoglycaemia and offer least glycaemic variability \[[@CR194]\].

The key clinical evidence in elderly population for various GLP-1 RAs is presented in Table [23](#Tab23){ref-type="table"}.

### Paediatric and Adolescents {#Sec350}

The uses of GLP-1 RAs are widely used in adults for glycaemic control and other benefits associated with the drug. Table [24](#Tab24){ref-type="table"} presented the key clinical evidence in paediatric and adolescent population.

###### 

GLP-1 RAs in special populations: paediatric and adolescents

  Study details                                                                                                   Aim                                                                                                                                                  Highlights
  --------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Exenatide                                                                                                                                                                                                                                                            
   Censani et al. \[[@CR202]\]. Case series \[*N* = 2\]. Duration 3--6 months                                     To report the effects of exenatide on metabolic risk and weight in adolescents with morbid obesity and T2DM                                          Exenatide treatment resulted in improvements in cardiometabolic risk factors^a^
  Liraglutide                                                                                                                                                                                                                                                          
   Klein et al. \[[@CR203]\]. Randomised, double-blind, placebo-controlled trial \[*N* = 21\]. Duration 5 weeks   To assess the safety, tolerability, PK/PD of liraglutide (monotherapy or combination therapy with metformin) in youth (10--17 years old) with T2DM   Liraglutide 1.8 mg:*t*~1/2~ = 12 h, clearance = 1.7 L/h. Liraglutide 1.8 mg resulted in greater decline in HbA1c level compared with placebo (-- 0.86 vs. 0.04%, *P* = 0.0007), no severe hypoglycaemia but transient GI AEs during dose escalation. Liraglutide 1.8 mg was safe and well tolerated
   Zhou et al. \[[@CR204]\]. Prospective randomised controlled trial \[*N* = 42\]. Duration 3 months              To evaluate the clinical efficacy of GLP-1 RAs for reversal of normal blood glucose in children with pre-diabetes                                    GLP-1 analogues were better as compared to control group owing to significantly lower FBG and 2 h PPBG levels (post 1 month) (*P* \< 0.01); statistically better controlled HbA1c, lipids and BMI (post 3 months); significantly decreased IR index (*P* \< 0.05); statistically higher values of the β-cell islet function index (*P* \< 0.05)

*AEs* adverse events, *BP* blood pressure, *BMI* body mass index, *FBG* fasting blood glucose, *GI* gastrointestinal, *GLP*-*1 RA* glucagon-like peptide-1 receptor agonist, *HbA1c* glycated haemoglobin, *IR* insulin resistance, *PD* pharmacodynamics, *PK* pharmacokinetics, *PPBG* postprandial blood glucose, *T2DM* type 2 diabetes mellitus

^a^Triglyceride levels, BP, FBG, HbA1c

### Sleep Apnoea {#Sec351}

The key clinical evidence on sleep apnoea for various GLP-1 RAs is presented in Table [25](#Tab25){ref-type="table"}.Table 25GLP-1 RAs in a special population: sleep apnoeaStudy detailsAimHighlightsLiraglutideBlackman et al. \[[@CR205]\]. SCALE Sleep Apnoea randomised, double-blind, placebo-controlled parallel-group trial \[liraglutide, *n* = 180; placebo, *n* = 179\]. Duration 32 weeksTo investigate whether liraglutide 3.0 mg reduces OSA severity versus placeboLiraglutide 3.0 mg resulted in (when compared to placebo) greater AHI mean reduction (− 12.2 vs. − 6.1 events/h, estimated treatment difference − 6.1 events/h \[95% CI − 11.0 to − 1.2\]; *P* = 0.0150); greater mean reduction in weight (− 5.7% vs. − 1.6%, estimated treatment difference − 4.2% \[95% CI − 5.2 to − 3.1%\], *P* \< 0.0001); greater reductions in HbA1c levels and SBP (both *P* \< 0.001)*AHI* apnoea--hypopnoea index, *GLP*-*1 RA* glucagon-like peptide-1 receptor agonist, *HbA1c* glycated haemoglobin, *OSA* obstructive sleep apnoea, *SBP* systolic blood pressure, *SCALE* satiety and clinical adiposity--liraglutide evidence in individuals with and without diabetes

### Fasting Conditions: Ramadan {#Sec35}

GLP-1 RAs do not cause hypoglycaemia; hence, dose adjustments or modification is not required during fasting days. The dose of GLP-1 analogues, liraglutide, exenatide or lixisenatide, should be the same as pre-Ramadan dose even when used with insulin. However, dose adjustments are required for insulin, sulfonylureas or any other antidiabetics which can cause hypoglycaemia when administered concomitantly with GLP-1 RAs. Other oral hypoglycaemic agents do not require dose adjustments. Table [26](#Tab26){ref-type="table"} presents the guidelines for the use of GLP-1 RAs during Ramadan.Table 26Guidelines for the use of GLP-1 RAs during RamadanSituation in pre-RamadanAction during RamadanSingle dose before breakfast. Exenatide may be used twice within 1 h before mealSame dose to be taken before Iftar. Exenatide same as pre-Ramadan before Iftar/or SahurGuidelines are for GLP-1RAs: liraglutide 0.6/1.2/1.8 mg, lixisenatide 10/20 µg and exenatide 5/10 µg*GLP*-*1 RA* glucagon-like peptide-1 receptor agonist

### Polycystic Ovary Syndrome {#Sec36}

PCOS is one of the most common endocrine disorders that affect women of reproductive age \[[@CR206]\]. PCOS is associated with high levels of androgen and insulin (hyperinsulinaemia) which contribute to the risk of developing disorders including obesity, high BP, high cholesterol, diabetes mellitus and CVD \[[@CR207], [@CR208]\]. Excess body weight is a key phenotype of PCOS wherein 60--70% of women with this condition are reported to be obese or overweight \[[@CR206]\]. Another common feature associated with PCOS is insulin resistance \[[@CR209]\].

Women with PCOS are 5--10 times more prone to the risk of developing T2DM, and the progression from impaired glucose tolerance to T2DM is faster in women with PCOS compared to women without PCOS (age and weight matched) \[[@CR210]\].

Reduction in body weight has been demonstrated to improve hyperandrogenism, reproductive function and metabolic parameters such as hypertension, hyperlipidaemia and glycaemic control in women with PCOS \[[@CR211], [@CR212]\].

GLP-1 RAs have expanded the treatment option for PCOS owing to their ability to influence both body weight and glycaemic control. These agents are also associated with a modest decrease in BP and improvement in hyperlipidaemia \[[@CR206]\]. The evidence on the use of GLP-1 RAs for the treatment of PCOS in women is currently available only for exenatide BID and liraglutide QD.

### Pregnancy and Lactation {#Sec37}

Animal studies have reported reproductive toxicity with all GLP-1 RAs and hence use of GLP-1 RAs is contraindicated during pregnancy. It is not recommended for use in breastfeeding women. Women of childbearing age are advised to use contraception during treatment \[[@CR213]\]. GLP-1 RA use in special population according to the prescribing information/package insert is summarised in Table [27](#Tab27){ref-type="table"}.Table 27Recommendations on GLP-1 RA use in special populationsPatients with \[[@CR42]--[@CR45], [@CR190], [@CR191]\]Dulaglutide QWExenatide BIDExenatide QWLiraglutide QDLixisenatide QDSemaglutide QWRenal impairment  Mild/moderate renal diseaseNo dose adjustment requiredCaution should be taken when initiating or escalating doseCaution should be taken when initiating a doseNo dose adjustments needed/to be used with caution in patients with dehydrationNo dose adjustments neededRenal function to be monitored in patients with renal impairment reporting severe GI symptoms  End-stage renal diseaseNo dose adjustment required/to be used with caution in patients with GI side effectsNot to be usedNot recommendedNot recommendedHepatic impairmentTo be used with caution/dose adjustment not neededPrimarily cleared by kidney/hepatic impairment does not affect blood concentrationNot studiedTo be used with caution/dose adjustment not neededNot studiedNo dose adjustment is recommendedH/O pancreatitisNot studied/other antidiabetic medications to be consideredNot studied/other antidiabetic medications to be consideredNot studied/other antidiabetic therapies to be considered--Not studied/other antidiabetic medications to be consideredNot studied/other antidiabetic medications to be consideredGeriatric patientsSubject to sensitivity (≥ 65) 0.75 mg is recommendedDose should be selected on the basis of renal function of the elderly patientsCaution should be taken when initiatingSubject to sensitivity (≥ 65 years)Subject to individual sensitivity (≥ 65 years)Subject to individual sensitivityPregnancyLimited data/only if the potential benefit justifies the potential risk to the foetus. Physician should be informedPhysician should be informedOnly if the potential benefit justifies the potential risk to the foetusOnly if the potential benefit justifies the potential risk to the foetus/physician should be informedLimited data. Physician should be informedLimited data with semaglutide use in pregnant womenLactationNo data on human milk/developmental and health benefits of breastfeeding should be considered along with the mother's clinical needCaution should be taken--No data on human milk. Developmental and health benefits of breastfeeding should be considered along with the mother's clinical need--No data on the presence of semaglutide in human milk, effects on the breastfed infant or effects on milk productionWomen of childbearing agePhysician to be informed if planning to get pregnantPhysician to be informed if planning to get pregnant--Physician to be informed if planning to get pregnant--To be discontinued in women at least 2 months before a planned pregnancy because of the long washout period for semaglutide-- not specified, *GI* gastrointestinal tract, *GLP*-*1 RA* glucagon-like peptide-1 receptor agonist, *H/O* history of

Checklists for GLP-1 RA Therapy Initiation {#Sec38}
------------------------------------------

GLP-1 RA therapy initiation is largely influenced by clinical requisites of patients. The criteria for patient selection for GLP-1 RA-based therapy, ideal patient type, rationale for initiation of different kinds of GLP-1 RA-based therapy and factors affecting the selection of the appropriate GLP-1 RA are discussed below.

Patient Selection and Rationale for GLP-1 RA-Based Therapy Initiation {#Sec39}
---------------------------------------------------------------------

Checklists for patient selection and rationale for GLP-1 RA-based therapy initiation are listed in Fig. [4](#Fig4){ref-type="fig"}.Fig. 4Patient selection and rationale for GLP-1 RA therapy initiation.*ASCVD* atherosclerotic cardiovascular disease,*CV* cardiovascular,*DKA* diabetic ketoacidosis,*GI* gastrointestinal,*GLP-1 RA* glucagon-like peptide-1 receptor agonist,*MEN2* multiple endocrine neoplasia,*MTC* medullary thyroid carcinoma,*NASH* non-alcoholic steatohepatitis,*PCOS* polycystic ovary syndrome,*SGLT2* sodium-glucose co-transporter-2

Factors Influencing the Selection of Appropriate GLP-1 Analogue {#Sec40}
---------------------------------------------------------------

An array of GLP-1 analogues are available on the market, and a few others are at various stages of approval to be released in the near future. Given the range and unique pharmacological properties, a patient-centred approach is feasible with this class of drugs. The factors that influence the choice of GLP-1 RA could be largely classified into biomedical and psychosocial factors \[[@CR214]\].

### Biomedical Factors {#Sec41}

Biomedical factors that dictate the choice of GLP-1 RAs consist of efficacy, safety and tolerability along with its versatility in combination with insulin \[[@CR214]\]. The efficacy of GLP-1 RAs largely depends on their ability to exert a stronger effect on either fasting or postprandial glucose. Long-acting agents are known to act on fasting blood glucose to a larger extent, whereas short-acting agents are known to have a greater effect on PPBG. Therefore, the choice of the drug could depend on the time when the patient is experiencing glucose fluctuations. Interestingly, GLP-1 RAs such as dulaglutide, liraglutide and lixisenatide are reported to have exhibited clinically relevant fasting and postprandial glycaemic benefits \[[@CR22], [@CR214], [@CR215]\].

The duration of action also determines the possible combination with insulin (short-acting insulin or basal) owing to their complementary pharmacology; theoretically, this combination influences both fasting and postprandial glucose \[[@CR214]\].

The choice of GLP-1 RAs may also be influenced by the anticipated AEs including upper and/or lower GI AEs which may vary among GLP-1 analogues and autonomic functions such as GI motility \[[@CR39], [@CR178], [@CR214], [@CR216]\].

Other factors to be considered are the effect of GLP-1 RAs on cardiac and renal systems and other comorbidities of concern \[[@CR214]\].

### Patient-Related Factors {#Sec42}

Psychosocial factors that affect the selection of GLP-1 RAs include the ability of the patient to self-inject, their meal patterns and adherence to the pre-specified time of injection, frequency of contact with healthcare providers, cost-effectiveness and so on \[[@CR214]\].

For a person who can self-inject, all GLP-1 RAs are equally feasible for use. Certain GLP-1 RAs require manual dexterity as a few of them need needle attachment, reconstitution and priming prior to injection. Injection frequency, discussed in a forthcoming section, is another important factor. The injection frequencies among GLP-1 analogues vary from twice-daily to once-weekly administration owing to different pharmacological profiles \[[@CR214]\].

Meal patterns may also influence the choice of GLP-1 analogues. Liraglutide is effective with all kinds of meal patterns adopted by patients. Exenatide BID may benefit patients who consume heavy breakfast and dinner, whereas those who take a light dinner may benefit from lixisenatide. Patients with irregular meal patterns and lifestyle who are at risk of hypoglycaemia may benefit from once-weekly drugs without major safety concerns \[[@CR214]\].

Another important psychosocial aspect is the cost associated with GLP-1 analogues. Currently, none of the agents are available generically and therefore all GLP-1 analogues have a relatively high cost \[[@CR178], [@CR214]\].

A few GLP-1 analogues have, however, demonstrated treatment satisfaction versus a few comparators such as sulfonylureas, insulin and DPP4 inhibitors \[[@CR217]--[@CR219]\].

Selection of Appropriate GLP-1 Analogue {#Sec43}
---------------------------------------

The efficacy and safety profiles vary among the GLP-1 RAs because of their varying pharmacokinetic profiles. Hence, GLP-1 RAs can be chosen on the basis of the clinical need of the patients. Table [28](#Tab28){ref-type="table"} illustrates the selection criteria based on the efficacy of GLP-1 RAs to act upon a clinical parameter.Table 28Selection of appropriate GLP-1 RAParametersGLP-1 RAShort-actingIntermediate-actingLong-actingGlycaemia  FBG++++++  PPBG+++++++Weight++++++++CVO+++++++Injection burden++++++Renal safety+++++GI intolerance++++++The number of '+' signs indicates the weighting for consideration of the parameter for respective therapy*CVO* cardiovascular outcomes, *FBG* fasting blood glucose, *GI* gastrointestinal, *GLP*-*1 RA* glucagon-like peptide-1 receptor agonist, *PPBG* postprandial blood glucose

Monitoring Checklist Specific for GLP-1 RA-Based Therapy {#Sec44}
--------------------------------------------------------

Proactive monitoring aids in improving therapeutic outcomes and preventing potential adverse drug effects. It provides essential information for the management of chronic conditions such as diabetes to both healthcare providers and patients. Figure [5](#Fig5){ref-type="fig"} lists the recommended procedures, lab tests and physical assessments to be performed or reviewed before and after the initiation of GLP-1 RA therapy.Fig. 5Monitoring checklist for GLP-1 RA-based therapy.*eGFR* estimated glomerular filtration rate,*GLP-1 RA* glucagon-like peptide-1 receptor agonist,*HbA1c* glycated haemoglobin

Injection Technique and Frequency {#Sec45}
---------------------------------

One of the main advantages of GLP-1 RAs with respect to mode of administration is the ready-to-use pens which improve adherence to therapy. Studies have reported favourable patient outcomes with pen delivery systems compared to vial or syringe systems \[[@CR220], [@CR221]\]. Table [29](#Tab29){ref-type="table"} compares the injection pens and delivery patterns of GLP-1 RAs.Table 29Comparison of injection pens and delivery patterns of GLP-1 RAsParameters GLP-1 RADelivery devicesTime to steady state^a^Administration frequency^b^Need to attach needle to penNeed to prime pen?Reconstitution requirementDulaglutide \[[@CR222], [@CR223]\]Single-dose prefilled pen (0.75 mg, 1.5 mg)2--4 weeksOnce weeklyNoNoNoExenatide BID \[[@CR223], [@CR224]\]Multi-dose prefilled pens (5 μg/dose, 10 μg/dose)Not reportedTwice dailyYesYesNoExenatide QW \[[@CR223], [@CR225]\]Single-dose, dual-chamber pen containing powder (2 mg) and solvent for prolonged-release suspension and single-dose prefilled pen for prolonged-release suspension (2 mg)6--7 weeksOnce weeklyYesNoYesLiraglutide \[[@CR223], [@CR226]\]Multi-dose prefilled pen (device delivers 0.6, 1.2 or 1.8 mg/dose)Not reportedOnce dailyYesYesNoLixisenatide \[[@CR223], [@CR227]\]Multi-dose prefilled pens (10 μg/dose, 20 μg/dose)^c^Not reportedOnce dailyYesYesNoSemaglutide \[[@CR50], [@CR51]\]Multi-dose prefilled pens (device delivers 0.25, 0.5 and 1 mg/dose)4--5 weeksOnce weeklyYesYesNoAll the above drugs should be refrigerated between 2 and 8 °C before their first use. Not to be kept in freezer and not be used if frozen. The devices should be protected from heat and sunlight*GLP*-*1 RA* glucagon-like peptide-1 receptor agonist^a^Approximate values^b^All GLP-1 receptor agonists administered subcutaneously^c^Also available as a treatment-initiation pack containing both doses of multi-dose prefilled pens

Dulaglutide has a hidden, ready-attached needle which requires no priming; this may help patients with fear of needles \[[@CR223]\]. Once-weekly doses reduce the injection burden on patients who are unwilling to self-inject, have aversion to needles and are unable to adhere to frequently administered therapy. This also helps patients who depend on caregivers for injections. Dulaglutide and semaglutide require once-weekly doses owing to their extended duration of action \[[@CR223]\]. Such once-weekly injections can also be administered as directly observed therapy which encourages regular patient--provider contact.

Combinations of GLP-1 RA and Insulin {#Sec46}
------------------------------------

As discussed earlier, many guidelines across the world recommend GLP-1 RAs along with insulin. Given the versatility of GLP-1 RAs, the rationale behind combining basal insulin with GLP-1 RAs is the fact that combination optimises the prandial endogenous insulin response to control PPBG and reduces the insulin dose requirement \[[@CR228]\]. Their complementary modes of action are known to improve glycaemic control in many patients with T2DM with no significant risk of hypoglycaemia and weight gain \[[@CR229]\]. In addition, fixed-ratio combination has the advantage of a less complex treatment regimen, with only one injection per day.

The USFDA has currently approved two titratable, fixed-ratio combination therapies for the treatment of patients with T2DM \[[@CR230]\]. Table [30](#Tab30){ref-type="table"} presents the fixed-ratio combination of insulin/GLP-1 RA currently available on the market along with the clinical evidence available on combination therapy.Table 30Fixed-dose basal insulin/GLP-1 RA combination product information and clinical evidence on basal insulin/GLP-1 RA combinationFixed-dose basal insulin/GLP-1 RAProduct informationDosing and administrationClinical evidence highlightsPackageStorageExpirationInitial doseTitrationMissed doseIDegLira: Insulin degludec/liraglutide (Xultophy^®^) \[[@CR231]\]3-mL pens, 5 packUnopened: Refrigerator Opened: Room tempUnopened: Expiration date Room temp: 21 days16 units2 units every 3--4 days, max 50 units/day1--2 days: resume with next scheduled dose; \> 3 days: 16 unitsDUAL-I, a phase 3, open-label, randomised, 26-week, treat-to-target trial reported IDegLira to be non-inferior to insulin degludec and superior to liraglutide. A significantly greater number of patients in the insulin degludec/liraglutide group achieved HbA1c \< 7%, weight loss and lower insulin requirements \[[@CR232]\]DUAL-II, a 26-week, randomised, double-blind trial (*N* = 413) reported that IDegLira was superior to IDeg, with significantly greater reduction in HbA1c (1.9% vs. 0.9%, *P* \< 0.0001) without hypoglycaemia or weight gain \[[@CR233]\]DUAL-V, a phase 3, multinational, multicentre, 26-week, randomised, open-label (*N* = 557), reported insulin degludec/liraglutide to be non-inferior compared to up-titration with glargine. Treatment with degludec/liraglutide compared with glargine showed a statistically superior HbA1c reduction (− 1.81% vs. − 1.13, *P* \< 0.001), weight loss of 1.4 kg vs. 1.8 kg weight gain and fewer hypoglycaemic episodes \[[@CR234]\]iGlarLixi: Insulin glargine/lixisenatide (Soliqua^®^) \[[@CR235]\]3-mL pens, 5 packUnopened: Refrigerator Opened: Room tempUnopened: Expiration date Room temp: 14 days\<30 units basal insulin or on lixisenatide: 15 units 30--60 units basal insulin: 30 units2--4 units weekly, max 60 units/dayResume with next scheduled doseLixiLan-O, a 30-week, randomised trial (*N* = 1170), reported iGlarLixi compared with insulin glargine and lixisenatide to be superior in HbA1c reductions (6.5% vs. 6.8% and 7.3%, respectively; both *P* \< 0.0001) along with improvement in adverse effects (hypoglycaemia, weight gain, nausea and vomiting) \[[@CR236]\]*GLP*-*1 RA* glucagon-like peptide-1 receptor agonist, *HbA1c* glycated haemoglobin

Quality of Life: GLP-1 RA-Based Therapy {#Sec47}
---------------------------------------

Quality of life associated with GLP-1 RA-based therapy is presented in an evidence-based manner as follows:

A study examined and compared patient perceptions of the injection devices used with liraglutide and dulaglutide. Patients with T2DM across the USA (*N* = 404, mean age = 60.7 years, 54.0% female; 204 liraglutide; 200 dulaglutide) were recruited for the study. Patients who had experience with both the treatments completed the Diabetes Injection Device Preference Questionnaire (DID-PQ) to report preferences between the two devices. Analysis of covariance was used to compare Diabetes Injection Device Experience Questionnaire (DID-EQ) scores. Although the mean DID-EQ item scores for both treatments were high (ranging from 3.48 to 3.90 on a 4-point scale), it was demonstrated that dulaglutide had higher scores than liraglutide on DID-EQ global items, which assessed the ease of use (3.82 vs. 3.73, *P* = 0.040) and convenience (3.79 vs. 3.66, *P* = 0.004). Among the 58 patients who had used both devices, more patients reported a preference for the dulaglutide device than the liraglutide device on every item of the DID-PQ \[[@CR237]\].

A study on the safe and effective use of dulaglutide single-dose pen in injection-naïve patients with T2DM reported that the majority of patients (\> 96%) found the device easy to use. They were satisfied with the pen, and were willing to continue and recommend the pen to others. A significant reduction in the fear of self-injection from baseline to the end of the study was also reported \[[@CR238]\].

Another prospective, observational study analysed the changes in health-related quality of life and emotional well-being in patients who had commenced GLP-1 analogue therapy (exenatide) in comparison with new insulin starters. At 6 months, the patient group treated with exenatide experienced significantly greater treatment satisfaction (*P* \< 0.05), well-being (*P* \< 0.05) and reduced hospital anxiety and depression scale scores (*P* \< 0.05) compared to the insulin-treated group. Results from multivariate analysis showed a cumulative significant effect (*P* \< 0.05) of exenatide analogue therapy on diabetes treatment satisfaction questionnaire and Well-Being Questionnaire 12 scores after controlling for the effect of BMI \[[@CR218]\].

Treatment satisfaction and improvement in the quality of life influence adherence to medications. A series of randomised trials assessed once-weekly administration of dulaglutide as an add-on therapy in patients with T2DM. The study reported improvement in perceived hypoglycaemia and treatment satisfaction as assessed by Diabetes Treatment Satisfaction Questionnaire (DTSQ) status and change version compared to placebo and exenatide BID at 26 and 52 weeks \[[@CR239]\].

A 52-week randomised, parallel-group, open-label trial compared the efficacy and safety of once-daily human GLP-1 analogue liraglutide (1.2 or 1.8 mg) with DPP4 inhibitor sitagliptin, added onto metformin in individuals with T2DM. DTSQ scores increased significantly (*P* = 0.03) more with liraglutide (1.8 mg) than with sitagliptin \[[@CR217]\].

A 52-week randomised, double-blind controlled trial investigated the patient-reported outcomes which included psychological well-being and distress in addition to other factors following treatment with liraglutide (1.2 or 1.8 mg) or glimepiride monotherapies in patients with T2DM. Glycaemic control and weight reduction were significantly greater in patients treated with 1.2 or 1.8 mg liraglutide (*P* \< 0.0001) compared to glimepiride which resulted in weight gain. Mental and emotional health, and general perceived health improved more with liraglutide (1.8 mg) than with glimepiride \[[@CR219]\].

Cost Implications {#Sec48}
-----------------

Cost-effectiveness plays a major role from the South Asian perspective wherein out-of-pocket health expenditure is witnessed by patients without any aid from the government \[[@CR240], [@CR241]\]. Listing GLP-1 RAs in the national list of essential medicines may reduce financial burden and pave the way for insurance benefits.

Barriers to Bridges: GLP-1 RA Therapy {#Sec49}
-------------------------------------

Adverse events associated with GLP-1 RAs are one of the major barriers for adherence to the therapy. The AEs most frequently associated with GLP-1 RAs are GI disorders, as evident from clinical trials and real-world studies \[[@CR242]--[@CR244]\]. The GI symptoms are reported to gradually subside with time and are dependent on the kind of GLP-1 RAs administered (short- or long-acting) \[[@CR39]\]. GI AEs may not affect glycaemic control but may be associated with greater weight loss \[[@CR245]\]. Among the GI symptoms, nausea and diarrhoea were reported to be the most common, followed by vomiting, constipation, abdominal pain and dyspepsia \[[@CR246]\]. The incidence of nausea is reported to vary between 25% and 60%, and its occurrence in specific individuals seems to be dependent on factors such as meal size, frequency and BMI \[[@CR39]\]. The other AEs include pre-renal acute injury, hypoglycaemia, injection site reactions, hypersensitivity, increase in heart rate and acute pancreatitis (proven in animal studies) \[[@CR39], [@CR178], [@CR214], [@CR216], [@CR246], [@CR247]\].

Counselling patients on mild and transient nature of symptoms, especially GI symptoms, may aid them to deal with unrealistic fears associated with AEs. Additionally, patient counselling about realistic expectations from the therapy may improve adherence to the therapy. The barriers associated with GLP-1 RA-based therapy and the ways to mitigate these barriers are presented in Fig. [6](#Fig6){ref-type="fig"}.Fig. 6Barriers to bridges in GLP-1 RA therapy.*AEs* adverse events,*F2F* face-to-face,*GI* gastrointestinal,*GIP* glucose-dependent insulinotropic polypeptide,*GLP-1 RA* glucagon-like peptide-1 receptor agonist,*HCP* healthcare practitioner,*PPI* proton pump inhibitor

Directly observed therapy (DOT) is an approach that facilitates patients to self-inject in the presence of a diabetes educator. This method is advantageous for both patient and the practitioner supporting the patient. It encourages regular patient--provider contact, which in turn facilitates early detection of AEs and complications and promotes more efficient lifestyle modifications \[[@CR22]\].

Conclusions {#Sec50}
===========

GLP-1 RAs, recognised as calorie restriction mimetics or calorie restriction facilitators, are relatively a newer class of injectable drugs in the pharmacological armamentarium for the management of T2DM. With benefits extending beyond glucose control, GLP-1 RAs are associated with extra-glycaemic effects including positive effects on weight, BP, cholesterol levels and β-cell function. Fortuitously, increasing evidence from large clinical trials aimed at studying CV episodes has also demonstrated CV risk reduction with GLP-1 RAs. The REWIND trial is anticipated to resolve the long-standing question on whether this class of drug could be beneficial in patient populations without an established CVD as their usefulness in patients with established CVD had already been demonstrated with a wealth of evidence. As GLP-1 RA therapy initiation is largely influenced by clinical requisites of patients, it is imperative that a pragmatic review of current evidence be integrated and applied in the context of an individualised patient-centred approach. However, there are quite a few unanswered questions on GLP-1 RAs such as long-term durability of their glycaemic effect, recommendation in the current cascade of therapy for T2DM, long-term safety concerns and so on. It is anticipated that the ongoing trials, in an evidence-based manner, will continue to fill these gaps and bring new paradigm shifts in diabetes care.
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